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ABSTRACT 
 
 
I investigate various dimensions of direct-to-consumer (DTC) advertising of 
antidepressant medication; specifically causes of depression, self-diagnosis, benefits and 
risks, and type of appeal used in the advertisements. My study tracks the history of 
depression, the development of antidepressant medication, and the regulation of 
psychotropic drug advertisements.   My data utilizes all advertisements that appeared 
since 1995 in the 26 most popular consumer magazines.  I analyze these advertisements 
both by brand and by what magazine the ad appeared in.  My findings indicate that this 
DTC advertising does an adequate job of addressing the causes of depression, does not 
overly encourage self-diagnosis, mentions side-effects more frequently than benefits but 
minimizes their severity, and overwhelmingly frames depression as a white, adult female 
condition.  
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I. INTRODUCTION  
 
Direct-to-consumer advertising of pharmaceuticals has become a topic of interest 
in the United States in recent years.  The U.S. is one of only two nations in the world 
that allow such advertising directly to the consumer, and the ramifications of this policy 
are still unknown.  The issues of whether such a policy should exist at all, or should 
continue but with more stringent regulations, is currently being debated.  Much research 
has been done on the subject, but controversy still remains.  The Federal Drug 
Administration’s Center for Drug Evaluation and Research conducted research on this 
topic and compiled a report to the nation in 2003.  They found both positive and 
negative effects of DTCA, especially on the doctor-patient relationship.  On the positive 
side, it was found to increase disease awareness.  The ads made consumers more aware 
of conditions and treatments as well as motivating patients to see their healthcare 
provider. On the other hand, several negative effects were found.  First, patients might 
demand drugs and physicians might feel pressure to prescribe such medication, hence 
increasing prescribing rates where they might be unnecessary.  In addition, both patients 
and doctors believed that the advertisements overstated drug efficacy and did not 
provide a fair balance of risks and benefits (CDER, 2005).   
In this study, I will examine the latter issue through an analysis of print 
advertisements for one class of psychotropic drugs: antidepressants.  The paper proceeds 
as follows.  In the next section, I will provide a brief history of clinical depression, 
antidepressant medication, pharmaceutical drug advertising and review the existing 
literature on psychotropic drug advertising.  In Section III, I describe my research 
objectives, the data I use, and my methods.  Section IV will present the results to my 
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analysis.  In the final section I discuss the implications for broader debate and make 
recommendations for potential policies. 
 
II. BACKGROUND INFORMATION 
  
A. How Depression Became A Clinical Disease 
1. The History of Clinical Depression and its Prevalence 
 Clinical depression is a serious mental illness that affects about 16 percent of the 
population on at least one occasion in their lives and is currently the leading cause of 
disability in the United States as well as other countries (Blanc, 1997; Murray & Lopez, 
1997).  Also known as severe depressive disorder or major depressive disorder, it is 
defined by the Encyclopedia Britannica as a “neurotic or psychotic disorder marked by 
sadness, inactivity, difficulty in thinking and concentration, a significant increase or 
decrease in appetite and time spent sleeping, feelings of dejection and hopelessness, and 
sometimes suicidal tendencies.”  Depressive disorders affect approximately 18.8 million 
American adults or about 9.5 percent of the U.S. population age 18 and older in a given 
year. The rate of diagnosed depression has almost doubled over the last fifty years.  
Nearly twice as many women (twelve percent) as men (seven percent) are affected by a 
depressive disorder each year (NIMH, 2006).   The following graph demonstrates the 
differences in risk of depression by gender as well as age.  Hazard rate refers to the 
chance an individual will incur the event each year per 1000 people (Cook & Leuchter, 
2001).   
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FIGURE 1 
 
RISK OF DEPRESSION BY AGE AND GENDER 
 
It is clear that the chance an individual will experience depression is higher for females 
than males at all ages, 9 – 44.  However, the hazard rate increased with age for both 
females and males.  Both genders experience peaks at 15 – 19 and 25 – 29.   
The severity of this disease is by no means minimal.  Depression will be the 
second largest killer after heart disease by 2020; fifteen percent of depressed people will 
commit suicide (WHO, 2001).  It results in more absenteeism than almost any other 
physical disorder and costs employers more than $51 billion per year in absenteeism and 
lost productivity, not including high medical and pharmaceutical bills. However, eighty 
percent of depressed people are not currently receiving any treatment.  Surprisingly, pre-
schoolers are the fastest-growing market for antidepressants, with at least four percent of 
preschoolers currently diagnosed as clinically depressed (Murray & Fortinberry, 2005).  
The use of antidepressants in pediatric patients as a whole has rapidly increased, 
especially over the past decade (Laurel et al, 2005).     
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The modern idea of depression links to the much older concept of melancholia, 
dating back to the time of the Ancient Greeks.  Although in its modern context 
"melancholy" applies to the mental or emotional symptoms of depression, historically 
"melancholia" could be physical as well as mental, and melancholic conditions were 
classified as such by their common cause rather than by their properties.  In historic 
writings there have always been observations of people “being blue”, “feeling sad for no 
reason”, or “having no motivation to do anything”.  For example, the Bible and works by 
Hippocrates and Homer contain subjects of melancholy.  However, the modern meaning 
and consequently diagnosis of depression itself did not exist before 1900.  Around the 
year 1900, a dominant figure in American psychiatry named Adolf Meyer proposed using 
the term depression to designate a downturn of mental energies, of an as yet unspecified 
nature. The concept of depressive psychoses began to take hold and became a staple in 
American psychiatry (Britannica, 2007). 
 
2.  The Current Method of Diagnosis: DSM-IV TR 
 An individual is diagnosed with depression when they meet a sufficient number of 
the symptom criteria for the spectrum suggested by the American Psychiatric 
Association’s Diagnostic and Statistical Manual of Mental Disorders or DSM.  The 
DSM is the handbook used most often in diagnosing mental disorders in the United 
States. The DSM has gone through five revisions (II, III, III-R, IV, IV-TR) since it was 
first published.  This manual was initially developed to give more objective terms for 
psychiatric research. Before its creation, communication between psychiatrists (especially 
in different countries) was difficult and hence diagnoses tended not to be uniform. The 
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establishment of specific criteria was also an attempt to facilitate mental health research. 
The multi-axial diagnostic system attempts to yield a more in-depth description of the 
condition. 
The classification system of the DSM and its subsequent categories are based on a 
process of consultation and meetings involving primarily psychiatrists. Therefore, the 
content of the DSM does not reflect all opinions on the subject of psychopathology, 
emotional distress and social functioning, nor are there any objective, biologically 
verifiable standards to which it adheres. The criteria, and the way they are applied by 
individual clinicians, are at least to some extent influenced by cultural variables and are 
periodically altered to reflect the contemporary social landscape.  There are currently no 
medical tests such as a brain scan or blood test for depression.  However, certain 
illnesses, including cardiovascular disease, hepatitis, mononucleosis, hypothyroidism, 
and organic brain damage caused by degenerative conditions such as Parkinson disease or 
Multiple Sclerosis may contribute to depression (NIMH, 2001).  
 
3. Symptoms of Depression 
 Clinical depression is characterized by interlocking physical, affective, and 
cognitive symptoms.  According to the DSM-IV-TR criteria for diagnosing a major 
depressive disorder, one of the following two elements must be present for a period of at 
least two weeks: 
• Depressed mood, or 
•    Anhedonia (a patient's inability to experience pleasure from normally 
pleasurable life events such as eating, exercise, and social/sexual interactions) 
 
12 
 
It is sufficient to have either of these symptoms in conjunction with five other symptoms 
over a two-week period.  These include: 
• Feelings of overwhelming sadness and/or fear, or the seeming inability to feel 
emotion (emptiness). 
• A decrease in the amount of interest or pleasure in all, or almost all, daily 
activities. 
• Changing appetite and marked weight gain or loss. 
• Disturbed sleep patterns, such as insomnia, loss of REM sleep, or excessive 
sleep (Hypersomnia). 
• Psychomotor agitation or retardation nearly every day. 
• Fatigue, mental or physical, also loss of energy. 
• Intense feelings of guilt, helplessness, hopelessness, worthlessness, 
isolation/loneliness and/or anxiety. 
• Trouble concentrating, keeping focus or making decisions or a generalized 
slowing and dulling of cognition, including memory.   
• Recurrent thoughts of death (not just fear of dying), desire to just “lay down and 
die” or “stop breathing”, recurrent suicidal ideation without a specific plan, or a 
suicide attempt or a specific plan for committing suicide. 
• Feeling and/or fear of being abandoned by those close to one. 
 
Other symptoms often reported but not usually taken into account in diagnosis include: 
• Self-loathing 
• A decrease in self-esteem. 
• Inattention to personal hygiene. 
• Sensitivity to noise. 
• Physical aches and pains, and the belief these may be signs of serious illness. 
• Fear of ‘going mad’. 
• Change in perception of time. 
• Periods of sobbing. 
• Possible behavioral changes, such as aggression and/or irritability. 
 
 
4. Causes of Depression 
A number of things are believed to contribute to clinical depression.  For some 
people, many factors seem to be involved, while for others a single factor can cause the 
illness.  Other times, people can become depressed for no apparent reason.   
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• Genetic - A family history of clinical depression increases the risk for 
developing the illness.  The National Institute of Mental Health declared in a 2004 
press release that “major depression is thought to be 40-70 percent heritable, but 
likely involves an interaction of several genes with environmental events” 
(NIMH, 2004) 
• Biological - People with depression typically have too little or too much of 
certain brain chemicals that transmit information called “neurotransmitters.”  
Changes in these brain chemicals may cause or contribute to clinical depression.   
• Cognitive - People with negative thinking patterns that are self-defeating and 
distorted as well as low self-esteem are more likely to develop clinical depression.   
Depressed people who are able to make corrections in their thinking patterns can 
show improved mood and self-esteem.   
• Gender – Women experience clinical depression at a rate that is nearly twice 
that of men.  Reasons for this phenomenon include the hormonal changes that 
women go through during menstruation, pregnancy, childbirth and menopause. 
• Situational – Early experiences such as death of a parent, abandonment or 
rejection, neglect, chronic illness, and physical, psychological, or sexual abuse 
can increase the likelihood of depression later in life.  Difficult life experiences 
including job loss, poverty, financial difficulties, divorce, or the death of a loved 
one can contribute to clinical depression.   
• Co-morbidity – Clinical depression is more likely to occur along with certain 
illnesses including: cardiovascular disease, hepatitis, mononucleosis, 
hypothyroidism, and organic brain damage caused by degenerative conditions 
such as Parkinson disease, Multiple Sclerosis, or Alzheimer’s disease (Britannica, 
2007). 
 
5. Types of Depression 
 Major Depression, or Major Depressive Disorder (MDD), is characterized by a 
severely depressed mood that persists for at least two weeks.  It is specified as either a 
“single episode” or “recurrent”.  Periods of depression may occur as discrete events or as 
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recurrent over the lifespan.  Clinical depression usually refers to acute or chronic 
depression severe enough to need treatment.  Episodes of major or clinical depression 
may be further divided into mild, major or severe.   
Diagnosticians further categorize several subtypes of Major Depressive Disorder 
including: Depression with Catatonic Features, Depression with Melancholic Features, 
Depression with Atypical Features, and Depression with Psychotic Features.  Other 
affective disorders related to depression include Dysthymia (long-term, mild depression 
that lasts for a minimum of two years), Bipolar I Disorder (an episodic illness in which 
moods may cycle between mania and depression), Bipolar II Disorder (an episodic illness 
defined primarily by depression but evidences episodes of hypomania), and Postpartum 
or Post-Natal Depression (clinical depression that occurs within two years of childbirth).    
It is important to discuss other non-depressive illnesses for which antidepressants 
might be prescribed for both off and on label use.  Antidepressants are useful in a range 
of disorders other than depression such as social anxiety disorder (SAD), generalized 
anxiety disorder (GAD) , post-traumatic stress disorder (PTSD), premenstrual dysphoric 
disorder (PMDD), and obsessive compulsive disorder (OCD).  Antidepressants can also 
sometimes help in bulimia nervosa. 
 
B. Development of Antidepressant Medication 
1. The Discovery of Antidepressants 
After World War II, an entire category of drugs was discovered to treat 
depression. The 1950s witnessed the emergence of two classes of psychotropic drugs: 
antipsychotics and antidepressants.  Antipsychotics or neuroleptics are a group of drugs 
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used to treat psychosis. Common conditions with which antipsychotics might be used 
include schizophrenia, mania and delusional disorders.  The term antidepressant refers to 
a drug that helps to rectify specific abnormalities that give rise to the symptoms of 
depression.   
In 1952, the first antipsychotic drug, chlorpromazine was discovered.  
Chlorpromazine was the first drug to show specificity for psychiatric disturbances and its 
sedative effects had an onset within only one hour.  The delayed effects were even more 
dramatic; patients who had been deluded and hallucinating for a decade emerged from 
their psychoses for the first time (Healy, 1997).  The use of chlorpromazine spread like 
wildfire through American asylums.  Though many were hesitant to view this drug as a 
“breakthrough,” the discovery was significant for the institution of psychopharmacology.   
The mix of elements that went into making chlorpromazine was essential to paving the 
way for antidepressant discovery.  
The first two classes of drugs used to treat major depression were the tricyclic 
antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs).  Like 
chlorpromazine, the development of the first TCA, imipramine, came from an interest in 
antihistamines.  It began as research on one specific compound and during 1950 was 
given to a wide range of clinicians to test (including some psychiatrists).  One of the 
psychiatrists asked to test the drug was Roland Kuhn, at the Münsterlingen Hospital near 
Konstanz, Germany. He treated over five hundred patients over a three-year period and 
found that this compound was a mood lifter without being a stimulant.  Patients 
experienced an increase in vivacity and a restoration of interest in activities and social 
interactions.  Sleep was restored in a normal and refreshing manner and appetite was 
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stimulated.  Kuhn also noted all the adverse effects which are now associated with TCAs.  
These include anxiety, sedation, weight gain, cardiac arrhythmias, orthostatic 
hypotension, and anticholinergic effects such as dry mouth, blurred vision, urinary 
retention, constipation and cognitive dysfunction.  From 1956 to 1957, many experts 
were called in to decide whether there would even be a market for such a compound.  
Though it is difficult to understand now, at this time depression was not seen as such a 
widespread illness and was suffered by most in silence.  In the United States, virtually all 
serious mental illness was diagnosed as schizophrenia.  Therefore, people who suffered 
the most extreme symptoms of depression, complete loss of sleep and appetite, were 
committed to asylums and given Electro convulsion therapy (ECT), (the popular 
treatment for schizophrenia).  At this time, there was no such thing as outpatient 
psychiatry. However, treatment using this compound was undeniably effective.  It was 
launched in Switzerland in November of 1957, and by the spring of 1958 it had been 
launched in a number of other European countries.  It was given the name imipramine 
(brand name Tofranil) and began being prescribed in the United States in 1959 (Healy, 
1997). 
The discovery of the monoamine oxidase inhibitor iproniazid in 1957 was the first 
“modern” antidepressant.  The discovery is credited to Nathan Kline who at the time was 
an assistant clinical professor of psychiatry at Columbia University and director of the 
research facility at Rockland State Hospital in New York.  Iproniazid was initially 
developed as an antitubercular drug in the early 1950s.   However, in addition to treating 
tuberculosis, it was observed by other clinicians to elevate mood and stimulate activity in 
many patients.  In 1956, Kline began a project to investigate the effects of iproniazid by 
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giving it to seventeen patients diagnosed as having schizophrenia.  It was found that two-
thirds of patients showed some response.  It was reported in newspapers at the time that 
patients were dancing in the wards even though they had holes in their lungs (Zeller et al, 
1952).  The New York Times informed the public at the time that “The drug…has 
produced ‘remarkable’ mood improvement and activity among long-term ‘untouchable’ 
psychotics of the ‘burned-out’ kind as well as among non-hospitalized neurotics.”  Soon 
thereafter iproniazid was widely prescribed to patients.  Within the first year it was 
available four hundred thousand depressed people were treated with this medication.  
However, MAOIs (like TCAs) have a number of adverse reactions which include 
sedation, confusion, and cardiac arrhythmias.  In addition, MAOIs are related to many 
drug-food interactions such as the tyramine reaction when MAOIs are combined with 
cheese, wines and beer.   
By the 1960s, recognition of depression as a mental illness began to increase.  The 
World Health Organization (WHO) set up studies to establish the prevalence of 
depression.  They concluded that up to 100 million people worldwide were probably 
depressed on any given day.  In 1958, Merck (a global research-driven pharmaceutical 
company established in 1891) approached a number of U.S. investigators including Nate 
Kline to investigate a molecule named amitriptyline for antischizophrenic properties.  
One of the investigators, Frank Ayd, realized that this molecule was almost identical to 
imipramine, and encouraged Merck to launch a trial of the compound for use in treating 
depression.  Results of these trials indicated that it appeared to help the same kind of 
patients that benefited from imipramine and had a similar dose range and side effects.  As 
a result of these trials, amitriptyline was launched in 1961 for the treatment of depression 
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by Merck and two other pharmaceutical companies (Roche and Lundbeck).  Through the 
efforts of these companies worldwide distribution was established and amitriptyline 
became the first commercially viable antidepressant product.  It became clear for the first 
time that there was money to be made out of antidepressants, even though the non-
hospitalized depression market was thought to be relatively small.   
Despite the fact that there were clear differences between the various compounds 
of antidepressants, they were grouped into one category of antidepressants sufficient to 
sustain sales.  This continued to be the case until the late 1970s.  During this time, 
pharmaceutical companies developed an increasing interest in the issues of the detection 
of depression in primary care and that in many cases depressive disorders needed long-
term treatment.  This led to a plethora of research that played a significant part in 
company decisions to proceed with the development of the next major class of 
antidepressants (Healy, 1997). 
 
2. Selective Serotonin Reuptake Inhibitors (SSRIs) and “Novel” Antidepressants 
Selective serotonin reuptake inhibitors (SSRIs) were developed in order to 
effectively work on the symptoms of depression without having the side effects of TCAs 
and MAOIs.  This is due to the specific pharmacologic activity of the SSRIs that 
precludes them from many of the problems of patience tolerance and toxicity associated 
with both TCA and MAOI use (Sanacore).    The establishment of SSRIs occurred over a 
relatively short period of time.  They were developed based on the knowledge gained 
from studying the effects of the TCAs.  As opposed to the chance discoveries of both 
TCAs and MAOIs, SSRIs were the result of ‘rational’ drug development.  This approach 
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specifically targets the fundamental brain mechanisms that are important in the 
pathophysiology underlying a syndrome such as depression.  The first SSRI to be 
marketed in the United States, fluoxetine (brand name: Prozac), was released in 1988 by 
the pharmaceutical company Eli Lilly.  After the infiltration of SSRIs into the 
antidepressant market, newer drugs were developed that are considered “novel” 
antidepressants.   They are SSRIs with unique mechanisms of action.  They were 
developed in an attempt to improve efficacy while decreasing side effects.  These include 
Selective-norepinephrine reuptake inhibitors (SNRIs), Norepinephrine reuptake inhibitors 
and Noradrenergic and specific serotonergic antidepressants (NaSSAs).   These classes of 
drugs have supplanted TCAs as the antidepressant of first choice by physicians because 
of their greater safety and tolerability as well as comparable efficacy.  The number of 
people using SSRIs and the newer “novel” antidepressants increased from 7.9 million in 
1996 to 15.4 million in 2001.  Simultaneously, the number of people using the older 
TCAs decreased from 2.3 million to 1.2 million.  It is clear from these statistics that the 
newer antidepressants are replacing the older drugs and that many more people are 
receiving such treatment (Zuvekas, 1996).  Table 1 is a history of all antidepressant 
drugs, their generic and brand names, category of antidepressant, and year of introduction 
(Bruck, 1992).   
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TABLE 1 
ANTIDEPRESSANT DRUGS, CATEGORY, AND YEAR OF INTRODUCTION 
GENERIC NAME BRAND NAME CATEGORY YEAR  
Phenelzine Nardil MAOI 1959 
Imipramine Tofranil TCA 1959 
Tranylcypromine Parnate MAOI 1960 
Isocarboxazid Marplan MAOI 1960 
Amitriptyline Elavil/Endep TCA 1961 
Desipramine Pertofran TCA 1963 
Nortriptyline Aventyl/Pamelor TCA 1963 
Protriptyline Vivactil TCA 1966 
Trimipramine Surmontil TCA 1966 
Iprindole Prondol TCA 1968 
Dothiepin Prothiaden TCA 1969 
Doxepin Adapin/Sinequan TCA 1969 
Clomipramine Anafranil TCA 1970 
Maprotiline Ludiomil NRI 1974 
Viloxazine Vivalin NRI 1974 
Butriptyline Evadyne TCA 1975 
Mianserin Bolvidon Tetra 1976 
Trazodone Desyrel Tetra 1980 
Lofepramine Gamanil TCA 1983 
Fluvoxamine Luvox SSRI 1987 
Amoxapine Asendis TCA 1989 
Fluvoxetine Prozac SSRI 1988 
Sertraline Zoloft SSRI 1991 
Paroxetine Paxil SSRI 1992 
Citalopram Celexa SSRI 1998 
Venlafaxine Effexor/Effexor 
XR 
SNRI 1993/ 
1997 
Nefazodone Serzone SNRI 1994 
Mirtazapine Remeron NaSSA 1996 
Bupropion Wellbutrin/ 
Zyban 
Norep 1996 
Escitalopram Lexapro SSRI 2002 
 
 
 
 
 
KEY 
MAOI = Monoamine oxidase inhibitor 
TCA = Tricyclic antidepressants 
SSRI = Selective serotonin reuptake inhibitor 
Norep = Norepinephrine reuptake inhibitor 
Tetra = Tetracyclic antidepressants and: 
NRI = Norepinephrine reuptake inhibitor 
SNRI = Selective-norepinephrine reuptake inhibitor 
SSRE = Selective serotonin reuptake enhancer 
NaSSA = Noradrenergic and specific serotonergic antidepressant 
21 
 
3. Proliferation 
In recent decades, there has been a significant increase in the overall rate of 
psychotropic medication prescribing, especially for antidepressants.  Over the last fifteen 
years antidepressants have been accepted among the mainstream patient population, and a 
recent study showed that physicians are prescribing antidepressant medications to their 
patients at a far greater rate than they did just two decades ago (Antonuccio et al, 2002).  
The prescription rate for antidepressants rose 34 percent between 1985 and 1999.  In 
1999, three of the top ten best-selling pharmaceuticals were the SSRIs Prozac, Paxil, and 
Zoloft, accounting for combined revenues of $6.7 billion (Antonuccio et al, 2002).  From 
2000 – 2001, $10.4 billion was spent on the four top-selling antidepressants alone: Zoloft, 
Paxil, Wellbutrin, and Celexa (In 2001, Lilly’s patent on Prozac expired) (Stefanova, 
2001).  Among adolescents, antidepressant use has also increased rapidly.  Overall, child 
antidepressant use increased by 9.2% each year from 1998 to 2002 (coy.state, 2005).   
The reader is referred to Table 2 for current National Rates of Treatment of 
Depression stratified by sociodemographic characteristics (Olfson et al, 2002). 
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TABLE 2 
 
In the ten year span of 1987 – 1997, national rates of treatment of depression increased 
from 0.73 per 100 population of treated depression to 2.33.  The sociodemographic 
characteristics of people that have the highest rates of treated depression are ages 18 – 64, 
white females, who are divorced or separated and unemployed.  In addition, there are 
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higher rates when the individual has completed an education beyond high school and 
receives public insurance. 
Though antidepressants were hailed in the 1980s and 1990s as a cure-all for the 
rapidly growing problem of depression, they may not be the panacea that everyone 
believes them to be; various problems exist in regard to this medication.  Sometimes they 
have intolerable side-effects that include: dry mouth, urinary retention, blurred vision, 
constipation, sedation, sleep disruption, weight gain, headache, nausea, diarrhea, 
abdominal pain, loss of libido, agitation and anxiety.  They do not work for 47% of the 
population and they may lose their effectiveness over time.  In fact, the FDA 
recommends taking them for no more than a short period of time (Murray & Fortinberry, 
2002).    
C. The History of Psychotropic Print Drug Advertisements 
 As soon as psychotropic drugs were invented, avenues developed to advertise 
them. The first major push in print psychotropic drug advertising in the United States 
began in the late 1940s.  Early advertisements were featured in professional medical 
journals and promoted both antipsychotic and antidepressant medication.  In a time when 
the country was recovering from the trauma of World War II, advertisements featuring 
these drugs promised ways to assist this wounded population.  The ads offered treatments 
for sleepless nights, psychoneurotic symptoms as well as an overall improved outlook on 
life.  The discovery of Chlorpromazine and iproniazid in the 1950s contributed to the 
establishment and subsequent growth of psychotropic drug advertising. 
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 Throughout the 1950s these advertisements expanded to include not only the 
“everyday person” but also were aimed at those mentally ill patients who were previously 
hospitalized.  As these individuals were trying to piece together their lives in the outside 
world, advertisements featured former patients working happily alongside other 
productive and “normal” citizens.  This first decade of psychotropic drug print 
advertising represented a social equilibrium where gender roles were solidified.  Families 
were reunited, men returned to work and women returned to their domestic 
responsibilities.  Over the next several decades and into the present, there was an 
explosion of psychotropic drug advertisements.  These advertisements (especially for 
antidepressants) have penetrated our mass media through print advertising and television.  
Undeniably, these advertisements have a powerful effect on our country’s prescription 
medication market (Rubin, 2004).  
 
1.  Pharmaceutical Marketing Regulations 
Regulations regarding prescription drug promotion are limited in many parts of 
the world.  As of 2004, less than one-sixth of countries had a well-developed system of 
drug regulation while one-third of countries had little to no regulatory capacity (Mintzes, 
2006).  The United States, on the other hand, has an agency that regulates prescription 
drug promotion directly. The Food and Drug Administration (FDA) is the federal agency 
responsible for ensuring drug safety and that these products are honestly, accurately and 
informatively represented to the public.  The Center for Drug Evaluation and Research 
(CDER), a sub agency of the FDA, assures that safe and effective drugs are available to 
the American people.  CDER was established to assess significant drug problems in the 
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marketplace on the eve of the 1906 Pure Food and Drugs Act.  This act prohibited 
interstate commerce of mislabeled and adulterated drugs.  Since this time, this agency has 
transformed and witnessed much important legislation on the issue of pharmaceutical 
drug advertising.   
The FDA began regulating the pharmaceutical industry in 1938 by addressing 
advertising to physicians.  These early regulations are still the standard by which all drug 
advertising is judged and applied today to consumer advertising. The FDA re-regulated 
the advertising of prescription drugs in 1962 under the Federal Food, Drug, and Cosmetic 
Act. These regulations established detailed requirements for ad content. On October 10, 
1962, President Kennedy signed into law the Drug Amendments of 1962, also known as 
the Kefauver-Harris Amendments. These Amendments required drug manufacturers to 
prove to the FDA that their products were both safe and effective prior to marketing. 
They also gave FDA control over prescription drug advertising (Berndt).  
Direct-to-consumer (DTC) advertising, the focus of my study, had its inception in 
the early 1980s with the first direct-to-consumer advertisement for a pneumonia vaccine 
Pneumovax® (Merck & Co., Inc.) which appeared in Reader’s Digest in 1981 (Woolshin 
et al, 2001).  As shown in Figure 2, the level of DTC advertising has grown considerably 
since 1994.  Spending stayed fairly steady between 2000 and 2002 then increased 
substantially from 2002 onward.   
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Source: IMS Health and Competitive Media Reports (Berndt, 248) 
FIGURE 2 
TREND IN DIRECT TO CONSUMER ADVERTISING SPENDING, 
1994−2004 
DTC advertising has been defined as “any promotional effort by a pharmaceutical 
firm to present prescription drug information to the general public through lay media.” 
DTC advertising of prescription drugs is legal in only the United States and New Zealand 
(Mintzes, 2006).  Since DTC advertising first appeared, it has generated a great deal of 
controversy.  Prescription drug companies have argued that these advertisements provide 
educational benefits to consumers.  They claim that this form of advertising is an 
advantage to consumers because they can gain access to information about disease and 
treatments and are prompted to discuss stigmatized conditions with their physician that 
they might otherwise not discuss, such as erectile dysfunction or depression.  In a sense, 
it is believed by some that DTC advertising “facilitates patient-physician interaction” 
(Curry et al, 2005).  Also, DTC ads can remind patients to get their prescriptions refilled 
and help them adhere to their medication regimens. On the other hand, many argue that 
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educational content in these advertisements is limited and that they are geared more 
toward promotion than education.   
In 1983, the FDA started to become concerned about the potential detrimental 
effects of these advertisements on the public.  They issued an advertising moratorium 
while they studied this issue.  They concluded that “direct to public prescription 
advertising was not in the public interest” (Cohen, 1988).  Regardless, the FDA granted 
drug companies the right to advertise directly to the public in 1985 due to concerns about 
freedom of speech as well as a general consensus that regulations already in place were 
sufficient enough to protect the consumer.  The FDA then set out specific guidelines that 
had to be followed (see Appendix 1).   In general, prescription drug ads must contain 
information in a "brief summary" relating to both risks and benefits. The specific criteria 
to be met included that they present true information about the side-effects of their drugs, 
and their contraindications and effectiveness.  In addition, advertisements cannot be false 
or misleading and cannot omit material facts. FDA regulations also call for "fair balance" 
in every product-claim ad.  This means that the risks and benefits must be presented with 
comparable scope, depth, detail, and that information relating to the product's 
effectiveness must be fairly balanced by risk information.  The FDA does not generally 
require prior approval of DTC ads, although companies are required to submit their ads to 
the FDA at the time they begin running. The agency, therefore, routinely examines these 
published DTC ads after they become available to the public. 
In 1997, the FDA modified its policy and relaxed their restrictions on DTC 
advertising.  It’s regulations of prescription drug advertising were clarified, particularly 
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for television ads.  Instead of requiring a “brief summary” of contradictions, side-effects, 
and effectiveness, advertisements only needed to include “major statements” of risks and 
benefits.  In addition, it was further required to provide information sources in addition to 
a physician, such as a phone number or website (Berndt, 223-4).  This new focus on 
consumers led to an explosion of DTC advertising, as well as huge increases in print and 
television advertising budgets.  Expenditures on DTC advertising more than quintupled in 
1997-2004 from $700 million in 1997 to more than $4 billion in 2004. The drugs that are 
advertised are limited in range; just 20 prescription drugs account for about 60 percent of 
the total industry spending on DTC advertising (Hollen, 2005).  
On August 2, 2005, the Pharmaceutical Research Manufacturers of America 
(PhRMA) released its voluntary code of conduct for DTC advertising of pharmaceuticals 
(see Appendix 2).  This code of conduct is not binding but instead may be voluntarily 
adopted by individual drug manufacturers.  Their release was the pharmaceutical 
industry’s efforts to repair their tarnished public image due to growing criticism of DTC 
advertising.  These concerns about the best interests of consumers still exist and are at the 
heart of the heated debate about DTC advertising (Grow et al, 2006).  
D.  Literature Review 
Several previous studies have investigated various relevant aspects of 
psychotropic drug advertisements.  In Gerry V. Stimson’s article, “The Message of 
Psychotropic Drug Ads,” he argues that psychotropic drug ads construct a certain type of 
reality where certain problems of living in the world are viewed as medical problems.   
He argues that these ads do not only define certain life events or situations as illnesses but 
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also define certain types of people as potentially in need of such drugs.  He claims that 
diagnostic criteria for the use of these drugs are vague, and that a clear message found in 
these advertisements is that women are more likely than men to be candidates for these 
drugs.  
A more recent study, “’Your Life is Waiting!’ Symbolic Meanings in Direct-to-
Consumer Antidepressant Advertising” by Jean M. Grow et al, was published in the 
Journal of Communication Inquiry in 2006.  This study is noteworthy because of its 
specific focus on the advertising of antidepressant medication.  Grow’s analysis 
demonstrates how pharmaceutical companies strategically frame depression with DTC 
advertising.  They analyzed six years of print advertising from August 1997 to August 
2003 in Reader’s Digest and Time and found that antidepressant advertisements privilege 
benefits over risks, fail to adequately educate consumers, and frame depression as a 
female condition.  One main weakness in this study is that the print advertisements used 
come only from Reader’s Digest and Time magazines; therefore their data is missing a 
number of advertisements that appeared in other magazines.  In addition, the 
advertisements they analyze only represent the three major brands: Prozac, Zoloft and 
Paxil.  However, this study is significant to my research because of their findings that 
risks as opposed to benefits are underprivileged in these ads both literally and 
symbolically.  Furthermore, they found that because depression is overwhelmingly 
framed as a female disease, it complicates diagnosis by perpetuating over diagnosis 
among females and under diagnosis among males (Grow et al, 2006).   
Another study relevant to my research is one that appeared in The Lancet in 2001 
titled “Direct-to-consumer advertisements for prescription drugs: What are Americans 
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being sold?”  Woolshin, Schwartz, Tremmel and Welch aim to establish what messages 
are being communicated to the public in DTC advertisements.  They found that within 
the 67 advertisements they analyzed, promotional techniques used included emotional 
appeals in 67% of the ads, and encouragement of consumers to consider medical causes 
for their experiences in 39% of the ads.  Furthermore, these ads described the benefits of 
medication in vague, qualitative terms (87%) more often than with factual data (13%).  
They found that only half of the advertisements used data to describe side-effects and it 
was generally indicated that these side-effects occurred infrequently. The methods they 
employed in their content analysis are similar to methods I will use in my research.  
However, though their results are significant, they use quite a limited time frame for their 
analysis.  Their sample used ten popular magazines, and examined only the first issue of 
every magazine in every other month between July, 1998 and July, 1999 (Woolshin et al, 
2001).   
The article “Suffering, Pharmaceutical Advertising, and the Face of Mental 
Illness” published by Joseph E. Davis is also relevant to my research.  In his article, 
Davis investigates how mental illness is usually represented in print ads, what such 
images signify about suffering, and what response they are designed to elicit.  He argues 
that if the function of DTC ads are to prompt sufferers of mental illness to recognize their 
problem and get professional help, then there is the idea that marketers can accurately 
capture and visually display how mental illnesses look and feel.  In doing so, they show 
very little distinction between mental illness and everyday suffering and use vaguely 
termed benefits over side-effects (Davis, 2006).  
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III. RESEARCH DESIGN 
A. Objectives of the Research 
In this thesis, I will investigate various aspects of antidepressant medication 
advertisements that appeared in magazines for a ten year period from November 1995 to 
August 2005. Specifically, I analyze the prevalence of four major dimensions of DTC 
advertising of antidepressants: causes of depression, self-diagnosis, benefits and risks, 
and type of appeal used in the advertisement.  I analyze whether there are any noticeable 
trends in how this information is conveyed based on the specific brand of antidepressant 
medication being advertised in addition to which magazines the ads appeared in.  I 
compare brands in order to examine the differences in how various manufacturers 
advertise their medication.  I will examine what magazines the ads appeared in order to 
determine if the appearance of ads and their characteristics are related to the demographic 
characteristics of the magazine readership.   
 
The following research questions will be examined in this thesis: 
1. Causes of depression:   
• How are the causes of depression represented in print advertisements for 
antidepressant medication?   
• Are they framed as medical causes (biological/chemical) or triggered by personal 
causes?  Or, do the ads claim that the cause of depression is both or unknown?   
• Do the causes of depression represented in print advertising vary by brand or by the 
target audience for each magazine?  
 
         These questions are important to any examination of antidepressant medication 
because, according to medical evidence, a number of factors are believed to contribute to 
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clinical depression and no specific cause has been identified.  There are, however, two 
main theories of causation.  The first is the biochemical theory.  This theory suggests that 
mental health disorders, including depression, arise “from internal causes…resulting in 
impaired social functioning” (Weiss & Lonnquist, 1997).  This theory posits that the 
causes are irregularities in brain chemistry.  The other main theory of causation is the 
psych-social theory.  This theory suggests that stressful personal and social situations 
trigger most depression.  Examples of stressful situations can include poverty, marital 
discord, death of significant others, and low self-esteem (Freden, 1982).  
       The biochemical theory operates to establish depression as a physiological problem 
and implies its symptoms can be treated as other similar somatic difficulties that regular 
physicians treat.  In addition, the chemical imbalance explanation excludes other possible 
explanations for the causes of depression that might negatively reflect on one’s character 
or personality.  By ruling out such an explanation, the biochemical theory provides 
comfort to those who suffer and would ultimately lead to more people taking 
antidepressant medication (Davis, 2006).  I would hypothesize that a majority of ads 
utilize this biochemical theory approach.    
 On the other hand, the psycho-social theory implies that medication is not the 
ultimate answer.  It would include references to psychiatrists, “mental illness,” or 
working through complicated issues.  I believe that a very small number of ads would 
include such references.  By straying away from the biochemical explanation for the 
causes of depression, the ads would also be reducing the possibility of efficacy for their 
product.  If the purpose of an ad is to increase sales, it is clear that pharmaceutical 
companies would limit the mentioning of psych-social causes.    
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2.  Self-diagnosis:  
• To what degree do print advertisements for antidepressant medication contribute to 
preliminary self-diagnosis versus physician consultation? 
• Does the degree to which these ads promote self-diagnosis versus physician 
consultation vary by brand or by the target audience for each magazine?   
 
The question of self-diagnosis is perhaps one of the most debated issues in the 
area of antidepressant medication advertisements.  Depression is undeniably a 
stigmatized illness because it often carries disgrace or shame stemming from the fear of 
being labeled according to stereotypes of people with mental health problems.  A 2005 
Australian study noted that around one quarter of people felt depression was a sign of 
personal weakness and would not employ someone with depression. Nearly one third felt 
depressed people "could snap out of it," and 42% said they would not vote for a politician 
with depression (www.heretohelp).  For this reason, consumers are sometimes hesitant to 
discuss depression with friends and family or to seek information from any mental health 
resource.  Therefore, it is fair to suggest that advertising of antidepressants may target a 
vulnerable population.  These advertisements can be a source of information for people 
who might not otherwise seek help.  Many contend that the objective of prescription drug 
advertisements is only to increase consumer-generated prescription volume.  Hence, it is 
possible that these advertisements provoke and facilitate an initial “self-diagnosis.” 
This is a major concern of antidepressant medication advertisements because of its 
impact on the doctor-patient relationship.  The degree to which this advertising promotes 
self-diagnosis contributes to an overall increase in prescribing rates.  When patients 
request a drug, prescribing rates go up “several fold” which suggest that “physicians may 
not be the stalwart intermediary that the law assumes.”   Furthermore, a study found that 
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close to 80% of physicians oppose these advertisements because they feel it impedes their 
ability to provide the best possible care to their patients (Kravitz et al, 2005).    It is 
important to see to what extent self-diagnosis is promoted through the use of a checklist 
of symptoms, a quiz/questionnaire, or a phone number/website because such items might 
inappropriately increase patient demand for antidepressants and negatively affect the 
physician-patient relationship.   
In this study I examine with what frequency the ads provide symptoms of 
depression and whether this varies by brand or magazine.   Specifically, what symptoms 
are referred to most frequently in the ads?  Also, I am interested in whether the symptoms 
are presented in a quiz or checklist format.  Though the listing of symptoms is a fairly 
standard technique of DTC advertising strategy, it is important to examine because they 
are often utilized to make consumers believe that a problem might exist that they did not 
recognize before or to define an everyday problem or experience in medical terms (Davis, 
2006).  Furthermore, I examinine how accessible these ads make it to gain more 
information about depression and its treatments.  With what frequency do they provide a 
phone number, website, or free information/booklets?  This can contribute to further self-
diagnosis or, on the other hand, can prompt a consumer to consult their physician.  The 
last aspect I look at is whether these ads clearly state to “ask/notify/see your doctor.”   
 
3.  Benefits and Risks:   
• Are benefits listed at all in the ads?  If so, which ones and how many are listed?   
• Are side-effects listed at all in the ads?  If so, which ones and how many are listed?  
• Does the frequency and method with which benefits and side-effects are presented 
vary by brand or by the target audience for each magazine?   
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The FDA requires that a pharmaceutical advertisement present true information 
about the side-effects of their drugs and call for a “fair balance” in product claims.  The 
general rule of thumb is to list the top three risks; however this may be grossly inadequate 
and reveal a clear lack of risk information (Davis, 2006).  In addition, the problem is 
further exacerbated when the ad claims that there is a low occurrence of side-effects, that 
they are not usually serious or that they are well tolerated.  This minimizes the severity of 
risks that undoubtedly exist.  Examining the frequency of benefits and risks is important 
in examining whether these ads lead to informed decision making by the consumer.  
Consumers are well served only when they can gain a thorough understanding of the 
overall risks, benefits, and treatment options.   
 
4.  Type of appeal used in the advertisement:   
• What types of appeals do print advertisements of antidepressant medications utilize?  
• What is the overall nature of the ad appeal?   
o Does the type of appeal vary by brand or by magazine? 
• What techniques are used to reach the target market?   
o How many of the ads include pictures of people?   
 Is depression portrayed as a primarily female or male disease? 
 What are their ages and races?   
o Do any of these techniques vary by brand or by magazine? 
• What other subtle messaging techniques are utilized? 
o What is the demeanor and social depiction of the people featured in the 
ads? 
o Do they use any “before/after” techniques to show changes in the 
demeanor or social depiction of people? 
o Do any of these more subtle techniques vary by brand or by magazine? 
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An ad appeal refers to how the advertisement convinces the consumer to purchase 
the product.  The nature of the ad appeal describes what marketing technique is used 
beyond the characteristics of the product.  Certain features are generally employed to 
attract the reader’s attention to the advertisement and contribute to the overall appeal.  
Many ads use more than one advertising technique, and these techniques can be explicitly 
conveyed or subtly referred to.  Visual representations and their interactions within the 
text in any advertisement are a crucial element in how consumers perceive 
advertisements.  I investigate what specific approaches are used in these ads.  Visual 
images of people are an excellent advertising technique because they are indicative of the 
target market these ads hope to reach.  Diagnosis of depression is consistently higher 
among females, at a rate of three females to one male (Copeland, 2001).  I investigate 
whether the advertisements reflect this statistic based on the frequency of gender in the 
advertisements.   
The more subtle messages of demeanor and social depiction of both males and 
females in these ads also are investigated.  This is important because the advertisements 
give accounts or explanations of why or how people come to have problems.  The 
message is that certain life events put people in a position where the prescribing of 
antidepressants might be appropriate.  The demeanor and social depiction of people in 
these ads is a fundamental way of conveying to the reader that problems may be work 
conditions, loneliness, personal finances, or relationships with other people.  However, 
instead of changing the situation, these problems can be resolved and the individual can 
adapt to the situation with the aid of medication (Stimson, 1975).  Many times images 
will depict sufferers in the grip of depression and this is usually signaled by their 
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physiognomy, posture, and passivity.  Other times, ads will show the sufferer after 
medication has begun and they are “changed.”  This is portrayed by their appearance and 
activity.  
I choose to focus on the advertisements themselves; to explore message content 
and their implied meanings.  I did not analyze the effect of these ads, the consumer 
response, or physician’s attitudes towards them as other studies have examined.  I 
focused on magazines as opposed to other forms of advertising because readers of 
magazines are likely to save advertisements for later use, a fact that is important to 
advertisers (Duuta-Bergman, 2004), and magazines have long been a medium well-suited 
to introducing new ideas into the mainstream.  Also, in 1997 the FDA passed new 
guidelines for television ads, which stated that prescription drug ads must refer people to 
more information through a toll-free number, a Web site, or references to print ads 
(Wilke, 1997).  In pharmaceutical advertisements there is an additional page listing a 
brief summary required by the FDA, but this directives page will not be included in my 
analysis. 
 
B. Description of Data 
In order to investigate the antidepressant medication advertisements, two different data 
sources will be used: 
1. The SCADS Archive  
The SCADS archive is a collection of all print advertisements for smoking 
cessation products, tobacco products, smoking-related public service announcements 
and prescription drugs that appeared between January 1985 and August 2005 in 26 
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consumer magazines.  The magazine set includes: Better Homes & Gardens, Black 
Enterprise, Business Week, Cosmopolitan, Ebony, Essence, Family Circle, Glamour, 
Good Housekeeping, Jet, McCall's (name changed to Rosie’s on January 1, 2001), 
Modern Maturity, Money, National Geographic, Newsweek, People, Playboy, Readers 
Digest, Rolling Stone, Seventeen, Sports Illustrated, Time, TV Guide, U.S. News 
&World Report, Vogue, and Women's Day. The SCADS database also includes 
advertisements from two medical journals: the Journal of the American Medical 
Association and the New England Journal of Medicine.  Ads in these two medical 
journals will not be included in this study since the focus is on direct-to-consumer 
advertising.   The magazines in the SCADS database were selected to represent 
magazines most frequently read by individuals with particular demographic 
characteristics.  22 groups were defined by race (3 groups), education (5 groups), 
income (5 groups), age (5 groups), gender (2 groups), and smoking status (2 groups). 
Readership data for the magazines that were used to select the magazines in the 
SCADS database were taken from Simmons National Consumer Survey (NCS).  The 
NCS is a repeated cross-sectional survey. The sample for each wave is independently 
drawn. The NCS employs a multi-stage stratified probability sample.  The final sample 
represents a representative probability sample of all adults living in households in the 
U.S. (excluding Hawaii and Alaska). In order to minimize respondent fatigue the data 
are collected in several phases. In Phase 1 respondents are interviewed (face-to-face). In 
Phase 1 interviewers collect demographic data and data on the magazines respondents 
read.  To collect this information interviewers present respondents with a deck of cards 
on each of which is printed the logo of one of the 182 magazines in the Simmons 
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sample.  If a respondent reports that he has read any portion of a magazine he is asked a 
set of questions about readership, including whether he reads the whole magazine.  
During the second part of Phase 1 respondents report, by filling out a questionnaire, 
whether they purchase and use specific products, including pharmaceutical products.  
Survey response rates in the NCS are generally high (approximately 70 percent) and 
compare well with other widely-used national surveys.  
Using the data on magazine reading from the 1998 NCS of the Simmons Survey 
of Media and Markets, the ten magazines most frequently read by members of each 
previously defined demographic group were chosen.  Although 22 groups were defined, 
members of each group often read the same magazines.  Consequently, instead of 220 
magazines, the final set includes the above 26 magazines.  Three magazines were 
unusable because not all the issues in the sample period could be located.  In those three 
cases the next most widely read magazine for the group in question were substituted.  
Using magazine circulation data from three independent sources, it was estimated that 
the 26 magazines in SCADS account for between 30.0 and 57.5 percent of magazines 
circulating in the US.  The lower figure is based on total circulation across 580 
magazines reported in Audit Bureau of Circulation’s (2003) Magazine Trend Report. 
The higher figure is estimated from readership data for the 172 magazines included in 
the NCS.  The SCADS magazines represent 5% of the 580 magazines in the Magazine 
Trend Report data but account for 30.0 percent of circulation.  
Each advertisement in the database is coded with the brand name, manufacturer 
name, length of advertisement, and position within the magazine.  Undergraduate 
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research assistants located the advertisements by examining the physical issues of the 
magazines and journals.  The advertisements were then scanned and stored electronically.  
Ten percent of the issues of each magazine were independently double-checked by a 
second research assistant.  If there was more than a ten percent error rate between the 
coders, all issues of that magazine were re-coded.  Another ten percent sample was 
double-checked and the process iterated until error rates of all checked samples were 
below five percent.      
The next step was to organize the advertisements into a system of “unique” 
advertisement binders.  Identical ads were given a unique ad number so that duplicate ads 
did not need to be coded more than once.  Unique advertisements are defined as an 
advertisement for an identified brand that contains different content than another ad for 
the same product, ranging from a difference of one extra word to a completely different 
advertising content. Even a small content change constituted classification as a unique ad.  
A unique ad can appear in a number of different magazines numerous times, but will only 
constitute as a single unique advertisement.  Certain differing features of the 
advertisement were not considered to constitute a new ad.  These include: ad size- as long 
as the ads are identical a change in size did not constitute a new ad.  In other words, when 
a two page ad goes to a one page ad or vice versa, as long as the words are the same, the 
picture the same, etc. it is not considered a new ad.  If the words or pictures get moved 
around, it is not a new advertisement, as long as everything stays proportionally similar; 
publication year- as long as the ads are identical a change in the copyright date also did 
not constitute a new ad; revision year- similarly, on the information pages, there is a date 
which indicates the month and the year the information was revised.  A change in the 
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revision date only did not constitute a new advertisement.  If even one word changes, 
however, it was considered a new advertisement.  Each unique ad was given a specific 
“unique ad number.”  .  
Advertisements for antidepressants were found in seventeen of the twenty six 
magazines:   
o Better Homes and Gardens 
o Cosmopolitan 
o Ebony 
o Essence 
o Family Circle 
o Glamour 
o Good Housekeeping 
o McCalls-Rosies 
o Newsweek 
o People 
o Reader’s Digest 
o Sports Illustrated 
o Time 
o TV Guide 
o U.S. News and World Reports 
o Vogue 
o Woman’s Day    
 
Advertisements for antidepressants were not found in the following nine magazines: 
o Black Enterprise 
o Business Week 
o Jet 
o Modern Maturity 
o Money 
o National Geographic 
o Playboy 
o Rolling Stone 
o Seventeen 
 
The magazines were categorized into four different groups based on a factor 
analysis of the demographics of the audiences for each magazine described in the Avery 
et al study (2006): Women’s magazines (Better Homes and Gardens, Good 
Housekeeping, TV Guide, Family Circle, McCalls-Rosies, and Woman’s Day), Young 
42 
 
Adults magazines (Vogue, Cosmopolitan, and Glamour), African American magazines 
(Ebony and Essence), and General Interest magazines (Newsweek, People, Reader’s 
Digest, Sports Illustrated, Time, and U.S. News and World Report).  
The brands that were found in these ads include: 
TABLE 3 
ANTIDEPRESSANT BRAND DATA 
BRAND MANUFACTURER DATE OF 
FDA 
APPROVAL
 
PATENT 
LOSS/  
TAKEN 
OFF 
MARKET 
DATE OF 1ST 
AD 
APPEARANCE 
IN DATA SET 
CELEXA Forest 
Pharmaceuticals 
July 1998  September 2001 
SERZONE Bristol-Myers 
Squibb Company 
December 
1994 
May 2004 December 1997 
EFFEXOR, 
EFFEXOR XR 
Wyeth 
Pharmaceuticals 
December 
1993, 
October 1997 
 November 1995, 
April 2003 
PROZAC Eli Lilly December 
1987 
January 
2002 
July 1997 
PAXIL CR GlaxoSmithKline February 
1999 
 September 2002 
WELLBUTRIN 
SR, 
WELLBUTRIN 
XL 
GlaxoSmithKline October 
1996, 
August 2003 
 Fall 1996, 
October 2003 
ZOLOFT Pfizer December 
1991 
 May 2001 
 
Prozac was the first antidepressant brand in my study to be approved by the FDA; 
however its patent was also the first to be lost.  Serzone was removed from the market by 
its manufacturer in May 2004.  This was shortly following a black box warning addition 
to its labeling due to concerns of associated liver failure.  Its generic form, nefazodone, 
however, is still on the market.  GlaxoSmithKline is the only manufacturer in my data set 
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to produce two brands: Paxil CR and the Wellbutrin SR and XL (which will be grouped 
together for analysis purposes).  Wellbutrin XL, which denotes extended release, was the 
latest brand in my data to be approved by the FDA.  Overall, after combining the 
Effexors and Wellbutrins, there are a total of seven brands included in my data.   
 
a. Instrument Development 
A content coding tool was used to record the content of the ads that was 
developed and tested as part of the funded project effort. This coding form is presented in 
Appendix 4.  The content coding form records: ad length, design of the ad (color/black & 
white), ad visual (whether it contains a picture, product, text, or chart/quiz/questionnaire), 
taglines, directives, side effects, product claims, general information about depression, 
offerings, nature of ad appeal, superiority claims, and whether people are in the ads (race, 
gender, age, etc).   
 
b. Pre-testing 
This coding instrument was pre-tested by several research assistants and the 
results were compared for consistency.  The instrument went through several rounds of 
testing and revisions until an acceptable level of inter-coder reliability was achieved 
(89%).  All advertisements were then coded using this instrument and rechecked for 
consistency and accuracy.  Inter-coder reliability was an essential part of this process.  
Ten percent of the coding forms of each magazine were independently double-checked 
by another research assistant.  If there was more than a ten percent error rate between the 
coders, all advertisements of that magazine were re-coded.  Another ten percent sample 
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was double-checked and the process iterated until error rates of all checked samples were 
below five percent.    
 
C. Methods 
I will be using a twofold strategy in my analysis.  First, I will analyze the aspects 
of the antidepressant advertisements on the unique ad level.  Since 1995, there have been 
69 unique advertisements for antidepressant medications that have been aimed directly at 
consumers.  By doing so, I can examine the advertisements to determine what messages 
the manufacturers are attempting to convey to the consumer and how these messages 
vary by brand/manufacturer.  Secondly, I will analyze the antidepressant advertisements 
using the frequency of ad appearance as my unit of analysis.  Many unique ads appeared 
multiple times across different magazines or on different dates within the same magazine.  
For each time an ad appeared, I will use analyze its content not by brand but by what 
magazine the ad appeared in. Through this analysis, I can investigate what messages the 
consumer is actually receiving through these advertisements.    
 
1. Variable Measurement 
Causes of Depression 
In order to examine this research question, I will note the frequency with which the 
following statements are made in the advertisements: 
•  “When you’re clinically depressed the level of serotonin may drop.” 
• “Depression could be caused by a chemical imbalance.” 
• “PMDD is related to hormonal changes and chemicals in your body.” 
• “It can be triggered by stressful life, or it can appear suddenly.” 
• “Depression is a real illness with real causes.” 
• “The cause of depression is unknown.” 
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I classified these statements into medical reasons such as biological or chemical factors 
(statements 1-3), personal reasons (statement 4), and unspecified/unknown causes 
(statements 5-6).     
 
Self-Diagnosis 
In order to examine the question of self-diagnosis, I will note the frequency of 
how many ads include symptoms of depression and what symptoms are referred to most 
frequently.  I will also observe whether the symptoms are presented in a quiz or checklist 
format.  In addition, I will be noting with what frequency the ads provide a phone 
number, website, or free information/booklets, as well as whether they state to 
“ask/notify/see your doctor.”   
I will use these measures in order to determine to what extent these ads facilitate 
self-diagnosis.  This will be accomplished by investigating the types of symptoms listed 
as well as exploring whether the ads provide a phone number or website to contact for 
more information or by offering free information/booklets.  Also, I will determine what 
percentage of the ads that provide symptoms present them in a quiz or checklist format.  
In addition, I will use these measures to determine how these ads might facilitate the 
doctor patient relationship by making a recommendation to “ask/notify/see your doctor.”   
 
Benefits and Risks 
In order to examine how benefits as compared to how risks are conveyed I will first 
note the frequency with which benefits and risks are listed on the unique ad level then 
repeat this analysis on the frequency level.    
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Benefits are product claims and include:  
General Health 
• Works to correct chemical imbalance 
Reproductive Health 
• Treats Pre Menstrual Dysphonic Disorder  
Psychological Health 
• Product helps treat Post Traumatic Stress Syndrome 
• Won’t change your personality 
General Claim 
• Low occurrence of side-effects/not usually serious/well tolerated 
• Not associated with weight gain 
• Not habit forming 
• Convenient 
 
Risks are possible side-effects listed in the ads and include:  
 
General Health 
• Sweating  
• Dizziness/ lightheadedness 
• Headaches 
• Rash 
• Seizure/tremor 
• Lack of energy/ weakness 
• Injury/ trauma 
• Vision impairment 
• Infection 
Gastrointestinal 
• Diarrhea, constipation, upset stomach 
• Nausea 
• Dry mouth 
• Sore throat 
Sleep Related 
• Insomnia 
• Drowsiness/ sleepiness/ yawn 
Sexual Side Effects 
• Sexual impairment 
Psychological  
• Anxiety/ nervousness/ agitation 
• Suicidal thoughts/ action 
• Decreased appetite 
Weight Effects 
• Weight changes/anorexia 
Cardiovascular 
• Increased blood pressure 
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I will use these measures in order to determine to what extent these ads lead to 
informed decision making by the consumer.  I will examine the percentage of the 
advertisements containing benefits of the drug and the percentage of the advertisements 
containing side-effects of the drug.   Specifically, I would like to discover how many 
advertisements minimize the risks by stating that side-effects have a low occurrence, that 
they are not usually serious or are well tolerated.  I will compare the frequency and 
framing of benefits and risks between brands in my unique ad analysis.   I will examine 
whether the method of presenting benefits and risks of antidepressant medication vary by 
magazine readership on the frequency level. 
 
 Type of appeal used in the advertisement: 
In order to examine the type of appeal utilized in the advertisements, I will 
examine a number of different features of ad appeal.  The first thing I will examine is the 
overall nature of the appeal.  The ads will be coded using only one of the following types 
of appeals representing the major or primary appeal used in the ad:  
• Anecdotal/testimonial- An anecdotal ad appeal is based on a specific person’s 
experience/story with the medication or illness.  These will have ads based on 
people’s subjective experiences with the product or condition.  An example is: 
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FIGURE 3 
EXAMPLE OF ANECDOTAL/TESTIMORNIAL AD: 
Zoloft Ad (Better Homes and Gardens, May 1995) 
 
• Motivational- A motivational ad appeal has a “you can do it” attitude.  It tries to pick 
you up and get you normal again by reaching out to the consumer and making them 
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feel like there is a solution to the condition.  An example of such is the Prozac ad 
below. 
 
FIGURE 4 
EXAMPLE OF MOTIVATIONAL AD: 
Prozac ad (Ebony, August 1997) 
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• Promotional- a promotional ad appeal’s focus is to promote the product through 
special offers, coupons, guarantees, promotions, etc.  Ads that preview a 
pharmaceutical that is soon to hit the market are always considered promotional.  An 
example is: 
 
FIGURE 5 
EXAMPLE OF PROMOTIONAL AD: 
Wellbutrin ad (Time, Fall 1996) 
 
• Emotional- an emotional ad appeal attempts to grab the consumer’s attention by 
trying to tap into the reader’s feelings and sentiments.  These ads do so by expressing 
either fears or anxieties the reader might be experiencing as well as the emotions they 
could feel after taking this medication.  An example of such is shown below. 
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FIGURE 6 
EXAMPLE OF AN EMOTIONAL AD: 
Paxil CR ad (Cosmopolitan, February 1993) 
 
• Popular appeal- A popular ad appeal makes you feel like you’re not alone and that 
many other people suffer from the same symptoms as you and take medication for it.  
An example of a popular appeal is shown below.   
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FIGURE 7 
EXAMPLE OF POPULAR AD: 
Effexor ad (Time, December 4th, 1995) 
 
• Safety- A safety ad appeal emphasizes how safe/low risk of side effects the 
medication is.  This is only part of the ad appeal if the advertisement makes a point 
to highlight the safety of the product.  An example of a safety ad is: 
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FIGURE 8 
EXAMPLE OF A SAFETY AD: 
Wellbutrin XL ad (Family Circle, August 8th, 2005) 
 
• Informative- An ad appeal that is informative gives empirical evidence of the 
medicine’s effectiveness or depicts the biochemical information behind the 
disease/medication.  An example of this type of ad appeal is shown below.  
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FIGURE 9 
EXAMPLE OF INFORMATIVE AD:  
Zoloft ad (Marie Claire, August 2001) 
 
The next dimension of appeal I am measuring is specific targeting techniques.  
First is the use of people in the advertisements. I will determine how many of the ads 
include pictures of people and how many people there are in each ad.  I will examine the 
gender, age groups and races of people appearing in the ads.  The last dimension of ad 
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appeal I am examining is the use of subtle messaging techniques.  I will measure the 
frequency of people that have a sad or stern demeanor, a happy or smiling demeanor, or 
have no particular expression.  I will also be measuring the frequency of how people are 
socially depicted: whether they are alone or with other people and if the latter, if this in a 
family, romance, work, or recreational setting.  I will further investigate these subtle 
messages when they are used in before/after picture techniques.  I will use these measures 
in order to describe the type of appeal mainly used in these ads and specifically within the 
three dimensions described above.   
 
V. RESEARCH RESULTS AND ANALYSIS 
A. Reporting of Results 
1. Analysis of Results at the Unique Ad Level 
 There are 69 unique antidepressant advertisements in my data set.   Of these 69 
advertisements, the frequency of each brand is as follows: 
TABLE 4 
 
BRAND FREQUENCY AT THE UNIQUE AD LEVEL 
 
BRAND MANUFACTURER N PERCENT
CELEXA Forest Pharmaceuticals 1 1.45% 
SERZONE Bristol-Myers Squibb Company 1 1.45% 
EFFEXOR & EFFEXOR XR Wyeth Pharmaceuticals 18 26.09% 
PROZAC Eli Lilly 15 21.74% 
PAXIL CR GlaxoSmithKline 3 4.35% 
WELLBUTRIN (SR & XL) GlaxoSmithKline 8 11.60% 
ZOLOFT Pfizer 23 33.33% 
TOTAL  69 100% 
 
 The brands that make up the majority of the unique advertisements are Zoloft 
(33.33%), Effexor and Effexor XR (26.09%), Prozac (21.74%), and the Wellbutrins 
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(11.60%).  Pfizer put out the most unique advertisements for its brand of antidepressant: 
Zoloft.  This brand makes up approximately 1/3 of all the unique advertisements.  
GlaxoSmithKline manufactures different brands of antidepressant medication; Paxil CR, 
Wellbutrin SR and XL are included in this data set.  Collectively, GlaxoSmithKline 
contributed to 15.95% of all the unique antidepressant advertisements, with the most 
being for the Wellbutrins.  Both Serzone and Celexa had one unique advertisement each.  
Effexor and Effexor XR (manufactured by Wyeth Pharmaceuticals) and Prozac 
(manufactured by Eli Lilly) constitute approximately half of all the unique antidepressant 
advertisements.  
 
Causes of Depression 
In order to examine this research question, I noted with what frequency the 
following statements are made in the advertisements.  Multiple causes may be stated in a 
single advertisement, so the total number of causes for each brand can exceed the number 
of unique advertisements for that particular brand.     
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TABLE 5: CAUSES OF DEPRESSION BY BRAND 
** multiple causes may be identified in a single advertisement, therefore numbers within each column do not add up to total # of ads
Celexa 
 
N = 1 
Serzone 
 
N = 1 
Effexor 
(XR) 
N = 18 
Prozac 
 
N = 15 
Paxil 
CR 
N = 3 
Wellbutrin 
SR & XL 
N = 8 
Zoloft 
 
N = 23
Total 
Biochemical/Medical Causes 
“When you’re clinically depressed the level 
of serotonin may drop.”  
0 0 0 9 0 0 0 9 
“Depression could be caused by a chemical 
imbalance.”  
0 0 16 6 2 0 8 32 
“PMDD is related to hormonal changes and 
chemicals in your body.”  
0 0 0 0 0 0 4 4 
Personal Causes 
“It can be triggered by stressful life, or it 
can appear suddenly.” 
0 0 0 13 0 0 0 13 
Causes are Unspecified/Unknown 
“Depression is a real illness with real 
causes.”  
0 0 2 15 0 0 0 17 
“The cause of depression is unknown.”  0 0 0 0 0 0 15 15 
TOTAL 0 0 18 43 2 0 27  
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In both Serzone’s and Celexa’s singular unique advertisements, none of these 
causes are listed.   Wyeth Pharmaceuticals manufactures Effexor and Effexor XR, which 
constitute 18 unique advertisements.  Wyeth references biochemical/medical causes in 
nearly every one of their advertisements.  Within Effexor’s three unique ads, one states 
that depression could be caused by a chemical imbalance and two claim that depression is 
a real illness with real causes.  Within Effexor XR’s fifteen unique ads, all of them 
mention that this medication “works on both serotonin and norepinephrine- two 
chemicals in the brain linked to depression.”  Therefore, both types of Effexor 
specifically state that depression is caused by a chemical imbalance or alludes to that fact.  
However, Effexor makes no mention of personal causes for depression.   
Prozac and Zoloft also mention biochemical/medical causes for depression.  
Advertisements for Eli Lilly’s antidepressant, Prozac, make several statements regarding 
the causes of depression in their advertisements.  Every Prozac ad states that “Depression 
is a real illness with real causes.”   Prozac further substantiates this claim by providing 
biochemical/ medical causes for depression.   A portion of the unique ads make the 
general statement that depression could be caused by a chemical imbalance and some 
specifically mention a neurotransmitter might cause depression by stating that “When 
you’re clinically depressed the level of serotonin may drop.”  However, Prozac does not 
only infer that depression is caused by medical reasons such as biological or chemical 
factors.  86.67% of the Prozac ads also mention that the causes of depression are not 
solely medical and can be triggered by stressful life, or it can appear suddenly.  Prozac is 
the only brand that mentions possible personal causes for depression.   
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Zoloft, with the greatest number of unique ads, also makes multiple statements 
within its ads about the causes of depression.  Like many other brands, Zoloft ads state 
that depression could be caused by a chemical imbalance.   Furthermore, Zoloft actually 
depicts this imbalance through the use of drawings which demonstrate the relevant 
neurotransmitters and the chemical imbalance.  Please refer to Figure 9 for an example. 
Zoloft also states in other unique ads a biochemical/medical cause that no other brand 
does; it claims that “PMDD is related to hormonal changes and chemicals in your body.”  
Zoloft is not the only brand that is prescribed for such a condition; Paxil, Prozac, and 
Celexa are as well.  However, Zoloft is the only brand that specifically advertises its use 
in treating such a condition.  Though Zoloft infers that both depression and PMDD can be 
caused by a chemical or hormonal imbalance, 65.22% of the ads also state that the cause 
of depression is unknown.  No other brand does this.  Also, it is important to note that 
Zoloft does not mention any personal causes.   
GlaxoSmithKline’s has two different brands of antidepressants- yet Paxil is the 
only one to discuss the causes of depression. 66.66% of Paxil CR’s three unique ads also 
claim that depression could be caused by a chemical imbalance but make no other 
statements regarding causes of depression.  Wellbutrin SR’s two unique ads and 
Wellbutrin XL’s six unique ads, similarly to Celexa and Serzone, contain nothing in their 
ads regarding the causes of depression.   
Overall, a biochemical/medical cause is claimed in 36 of the 69 unique 
advertisements.  Personal causes are claimed in 13 of the 69 unique ads.  The claim that 
depression is a real illness with real causes is claimed in 17 out of 69 ads and claiming 
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that the cause is unknown is made in 15 of the 69 unique ads.  Therefore, the most 
widespread claim regarding causes is of a biochemical/medical nature.   
 
2. Self-Diagnosis 
In order to examine the question of self-diagnosis, I noted the symptoms of 
depression and how many of the 69 ads these symptoms appear in.   
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** multiple symptoms may be identified in a single advertisement, therefore numbers within each column do not add up to total # of ads 
 
TABLE 6: SYMPTOMS OF DEPRESSION BY BRAND 
 Celexa 
 
N = 1 
Serzone 
 
N = 1 
Effexor 
(XR) 
N = 18 
Prozac 
 
N = 15 
Paxil 
CR 
N = 3 
Wellbutrin 
SR & XL 
N = 8 
Zoloft 
 
N = 23 
Total 
SEVERELY PSYCHOLOGICAL 
Everyday life unbearable 0 0 0 15 0 0 12 27 
Thoughts of Death/ Suicide 0 0 3 0 0 1 0 4 
PSYCHOLOGICAL 
Inability to Concentrate 1 0 0 14 2 0 0 17 
Loss of Interest 0 0 18 0 2 1 11 32 
High Stress/ Anxiety 0 1 0 0 1 0 10 12 
PHYSICAL ACTIVITY CHANGE 
Change in Sleep Patterns 1 1 3 15 2 0 9 31 
Change in appetite 1 0 3 15 0 0 0 19 
Fatigue/Low energy 0 1 18 15 0 0 13 47 
DEPRESSIVE SYMPTOMS 
Depression/ Sadness 0 1 15 15 1 1 14 47 
Sadness lasts weeks 0 1 3 0 0 0 1 5 
OTHER 
Agitation/ irritability 1 0 0 15 2 0 5 23 
Restlessness 0 0 0 0 2 0 0 2 
TOTAL 4 5 53 104 12 3 75  
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The symptoms that appear most frequently in unique antidepressant 
advertisements are depression/sadness (47 times), fatigue/low energy (47 times), loss of 
interest (32 times), and change in sleep patterns (31 times).  Certain brands tend to list 
some symptoms of depression over other ones.  The one Celexa unique ad mentioned the 
symptoms: change in sleep patterns, inability to concentrate, change in appetite, and 
agitation/irritability.  Effexor mentions loss of interest and fatigue/low energy in all of its 
18 unique advertisements.  In only three unique ads does this brand mention change in 
sleep patterns, change in appetite, thoughts of death/suicide, or sadness that lasts weeks.  
In all but three ads, depression/sadness is listed as a symptom of depression.  Paxil has 
three unique ads.  Many symptoms appear in any combination of two of these ads: 
inability to concentrate, loss of interest, change in sleep patterns, agitation/irritability, and 
restlessness.  Two other symptoms only appear in one of the unique Paxil CR ads: 
depression/sadness and high stress/anxiety.   
Prozac has 15 unique ads and lists certain symptoms in every one of their unique 
ads.  These include: everyday life unbearable, change in sleep patterns, change in 
appetite, fatigue/low energy, depression/sadness and agitation/irritability. Inability to 
concentrate is also listed as a symptom in all Prozac unique ads but one.  Serzone’s one 
unique ad lists the following symptoms: change in sleep patterns, fatigue/low energy, 
depression/sadness, sadness that lasts weeks, and high stress/anxiety.  It also includes the 
“other” symptom of a feeling of hopelessness.  Wellbutrin SR’s two unique ads list no 
symptoms of depression whatsoever.  Wellbutrin XL utilizes three symptoms and each 
symptom only appears in one unique ad.  These include loss of interest, thoughts of 
death/suicide, and depression/sadness.   Symptoms are included in all of Zoloft’s 23 
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unique advertisements.  They are listed with varying combinations but include: everyday 
life unbearable, loss of interest, change in sleep patterns, fatigue/low energy, 
depression/sadness, sadness that lasts weeks, high stress/anxiety, and agitation/ 
irritability. 
Overall, Prozac claims the greatest number of symptoms in their unique 
advertisements (104) followed by Zoloft (75) and Effexor (53).  The types of symptoms 
mentioned most often are physical activity changes (97 times), physiological symptoms 
(61 times), followed by depressive symptoms (52 times).   
I also observed whether the symptoms are presented in a quiz or checklist format.  
The use of this method within these advertisements could contribute toward self-
diagnosis and an overall increase in prescribing rates.  Therefore it is important to see to 
what extent these ads are including such items that might inappropriately increase patient 
demand for antidepressants and negatively affect the physician-patient relationship.   
Results indicate that Zoloft and Effexor (XR) are the only brands that utilize this 
method.  However, though only two brands are doing so, Zoloft and Effexor make up 
59.42% of the antidepressant unique advertisements.  Seven of the 23 unique Zoloft ads 
(30.43%) include a quiz.  Fifteen of the 18 unique Effexor (XR) ads (83.33%) include a 
quiz and three include a checklist like the one shown below. By doing so, these ads are 
encouraging the reader to compare certain aspects of their lives to the symptoms of 
depression.   The reader needs only to check off a certain number of boxes or answers 
“yes” to enough questions in order to self-diagnosis themselves with depression.  The ad 
below states that “if you answer yes to five or more of these questions then you should 
consider speaking to health care professional about the different treatment options for 
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depression.”  They direct the reader to discuss treatment options without even 
questioning the issue of diagnosis.   An example of an Effexor ad which utilizes this 
checklist approach is shown below. 
 
FIGURE 10 
EXAMPLE OF A SYMPTOM CHECKLIST: 
Effexor ad (Time, December 4th, 1995) 
 
A total of 22 of the 69 unique advertisements utilize this approach (31.88%).  Therefore, 
on the unique ad level, though only two brands do this, this method appears with 
substantial frequency. 
In addition, I noted with what frequency the ads provide a phone number or 
website (required after 1997), or free information/booklets, as well as whether they state 
to “ask/notify/see your doctor.”  By offering the reader a way to contact the manufacturer 
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(through a phone number or website) or to provide the reader with more information 
upon request could possibly facilitate self-diagnosis.   On the other hand, to state that the 
reader should “ask/notify/ see your doctor” would promote meeting with a doctor first. 
The overall frequencies of unique ads in which these things appear are: 
TABLE 7: ASPECTS OF SELF-DIAGNOSIS BY BRAND 
 
Every brand offers additional information through the use of a phone number, 
website, or both in at least some of their unique advertisements.  In every single ad but 
one, there is also a suggestion to ask, notify, or see your doctor.  The one exception is one 
unique ad by Wellbutrin SR.  This can be explained by the fact that one Wellbutrin SR 
unique ad is a promotional ad that simply says that Wellbutrin SR is coming soon (see 
Figure 5).  This is considered a “teaser” ad.  However, the other Wellbutrin SR ad 
contains both a phone number and website.  Prozac and Zoloft are the only brands that 
offer free information or a booklet. Zoloft even offers to send the reader a free starter kit 
as shown in the example below. 
 
 Celexa 
 
N = 1 
Serzone
 
N = 1 
Effexor 
(XR) 
N = 18 
Prozac
 
N = 15 
Paxil 
CR 
N =3
Wellbutrin 
SR & XL 
N = 8 
Zoloft
 
N =23
Total
Phone 
number 
1 1 15 2 3 7 23 52 
Website 1 0 15 8 3 7 23 57 
Free info/ 
booklet 
0 1 0 2 0 0 4 7 
Ask/notify/ 
see your 
doctor 
1 1 18 15 3 7 23 68 
TOTAL 3 3 48 27 9 21 73  
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FIGURE 11 
EXAMPLE OF AD OFFERING FREE INFORMATION: 
Zoloft ad (Woman’s Day, October 5th, 2004) 
 
67 
 
3. Benefits and Risks 
In order to examine how benefits as compared to how risks are conveyed I first noted 
the frequency with which benefits are listed in the unique ads.   The benefits appeared 
with the following frequencies in the unique advertisements:
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TABLE 8: BENEFITS OF MEDICATION BY BRAND 
** multiple benefits may be identified in a single advertisement, therefore numbers within each column do not add up to total # of ads
 Celexa 
 
N = 1 
Serzone 
 
N = 1 
Effexor 
(XR) 
N = 18 
Prozac 
 
N = 15 
Paxil 
CR 
N = 3 
Wellbutrin 
SR & XL 
N = 8 
Zoloft 
 
N = 23
Total 
General Health 
Works to correct chemical imbalance  0 0 15 0 0 0 15 30 
Reproductive Health 
Treats Pre Menstrual Dysphonic Disorder 0 0 0 0 0 0 4 4 
Psychological Health 
Product helps treat Post Traumatic Stress 
Syndrome 
0 0 0 0 0 0 2 2 
Won’t change your personality 0 1 0 14 0 0 0 15 
General Claim 
Low occurrence of side-effects/ not 
usually serious/ well tolerated 
0 1 0 15 3 1 15 35 
Not habit forming 0 1 0 2 0 0 14 17 
Not associated with weight gain 0 0 0 0 0 1 4 5 
Convenient 0 0 0 0 0 5 0 5 
TOTAL 0 3 15 31 3 7 64  
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The various brands of antidepressants claim differing benefits.  This is most likely 
due to the diverse pharmacology in each medication.  Both Celexa and Wellbutrin SR 
claim none of these benefits in their unique ads.  Zoloft is the brand that claims the most 
benefits throughout its 23 unique advertisements.  65.22% of the unique ads for Zoloft 
make the general health claim that their medication works to correct a chemical 
imbalance.  Effexor (XR) is the only other brand to make this claim (and claims no other 
benefit); it does so in 83.33% of its 18 unique advertisements.   Zoloft also claims the 
benefit that there is a low occurrence of side-effects, that they are not usually serious or 
that they are well tolerated in a substantial amount of their unique ads: 65.22%.  Zoloft is 
also the only brand to make a benefit regarding reproductive health that it treats Pre 
Menstrual Dysphonic Disorder; it does so in 17.39% of their unique ads.   In fact, these 
unique Zoloft ads that make this claim utilize the benefit as the focus of their 
advertisement.  One example is shown below. 
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FIGURE 12 
EXAMPLE OF AD CLAIMING REPRODUCTIVE HEALTH BENEFIT: 
Zoloft ad (Better Homes and Gardens, February 2003) 
 
In addition, Zoloft is the only brand to claim that it treats Post Traumatic Stress 
Syndrome and does so in 8.70% of its unique ads.  The other psychological health claim, 
that the medication will not change one’s personality, is a benefit only mentioned by 
Serzone (in 100% of its unique ads) and Prozac (in 93.33% of its unique ads).  In fact, in 
Serzone’s one unique ad and Prozac’s fifteen unique ads, they make the same three 
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claims with differing frequencies.  They both mention the benefit that there is a low 
occurrence of side-effects, that they are not usually serious or are well-tolerated; Prozac 
does so in 100% of its unique ads.  In addition, they both claim that their medication isn’t 
habit forming.  Prozac only does so in a small percentage of their unique ads, 13.33%.   
Wellbutrin XL is the only brand that claims its medication is “convenient” in 100% of its 
unique ads.  In addition, Wellbutrin XL claims once that there is a low occurrence of 
side-effects, that they are not usually serious or are well tolerated and in one other unique 
ad claims that the medication is not associated with weight gain.   
 Overall, Zoloft and Prozac claim the most benefits over any other brand.  The 
benefits most frequently stated are that there is a low occurrence of side-effects, that they 
are not usually serious or that they are well tolerated (35 times). The other frequently 
stated benefit is the general health claim that the medicine works to correct a chemical 
imbalance (30 times).  Zoloft is the only brand to make any benefits regarding Pre 
Menstrual Dysphonic Disorder or Post Traumatic Stress Syndrome, though Zoloft is not 
the only antidepressant prescribed to treat such conditions. 
In order to examine how benefits as compared to how risks are conveyed I then noted 
the frequency with which risks are listed in the ads.   The risks appeared with the 
following frequencies: 
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TABLE 9: RISKS OF MEDICATION BY BRAND 
 Celexa 
 
N = 1 
Serzone 
 
N = 1 
Effexor 
(XR) 
N = 18 
Prozac 
 
N = 15 
Paxil 
CR 
N = 3 
Wellbutrin 
SR & XL 
N = 8 
Zoloft 
 
N = 23
Total 
General Health 
Sweating  1 0 18 0 3 0 4 26 
Dizziness/ lightheadedness 0 1 18 0 3 3 0 25 
Headaches 0 0 0 15 1 0 0 16 
Rash 0 0 0 15 0 0 0 15 
Seizure/tremor 1 0 0 0 2 7 0 10 
Lack of energy/ weakness 0 1 3 0 2 0 0 6 
Injury/ trauma 0 0 0 0 2 0 0 2 
Vision impairment 0 0 0 0 2 0 0 2 
Infection 0 0 0 0 2 0 0 2 
Gastrointestinal 
Diarrhea, constipation, upset stomach 1 1 18 15 3 6 23 61 
Nausea 1 1 18 0 3 1 23 53 
Dry mouth 1 1 18 0 2 7 23 52 
Sore throat 0 0 0 0 0 3 0 3 
Sleep Related 
Insomnia 1 0 15 15 2 7 23 63 
Drowsiness/ sleepiness/ yawn 1 1 18 15 3 0 23 61 
Sexual Side Effects 
Sexual impairment 1 0 17 0 3 0 22 43 
Psychological 
Anxiety/ nervousness/ agitation 0 0 18 14 2 0 0 34 
Suicidal thoughts/ action 0 0 0 0 0 2 4 6 
Decreased appetite 0 0 0 0 2 0 0 2 
Weight Effects 
Weight changes/ anorexia 0 0 18 0 0 6 0 24 
Cardiovascular 
Increased blood pressure 0 0 18 0 0 7 0 25 
TOTAL 8 6 197 89 37 49 145  
** multiple risks may be identified in a single advertisement, therefore numbers within each column do not add up total # of ads 
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The different risks are mentioned with varying frequencies within each brand.  
Again, it is important to note that this is probably due to their varying pharmacology.  In 
Celexa’s one unique advertisement, the risks mentioned are sweating, seizure/ tremor, 
diarrhea/ constipation/ upset stomach, nausea, dry mouth, all sleep related side effects, 
and sexual impairment.  In Serzone’s one unique ad the same gastriointestinal risks as 
Celexa are mentioned but also states that the medication may cause 
dizziness/lightheadedness, lack of energy/weakness, as well as drowsiness/ sleepiness/ 
yawn.  Effexor (XR) mentions more risks in their unique ads than any other brand.  In 
100% of their unique advertisements, they mention the risks of sweating, dizziness/ 
lightheadedness, diarrhea/ constipation/ upset stomach, nausea, dry mouth, drowsiness/ 
sleepiness/yawn, anxiety/ nervousness/ agitation, weight effects, and increased blood 
pressure.  In 94.44% of their unique ads they mention sexual impairment and in 83.33% 
they mention insomnia.  After Effexor (XR), Zoloft mentions the most risks of taking this 
antidepressant.  They claim sleep related side effects as well as the same gastrointestinal 
side effects as Effexor (XR) in 100% of their unique advertisements.  In 95.65% they 
mention sexual side effects and in 17.39% of their unique ads they also mention sweating 
and suicidal thoughts/ action.  Prozac mentions headaches, rash, diarrhea/ constipation/ 
upset stomach and sleep related side effects in 100% of their ads.  They also mention 
anxiety/nervousness/ agitation in 93.33% of their unique ads.  For Paxil, 100% of their 
three unique ads list the risks of sweating, dizziness/ lightheadedness, diarrhea/ 
constipation/ upset stomach, nausea, drowsiness/ sleepiness/ yawn, and sexual 
impairment.  In 66.67% of Paxil CR’s ads they claim seizure/tremor, lack of energy/ 
weakness, injury/ trauma, vision impairment, infection, dry mouth, insomnia, anxiety/ 
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nervousness/ agitation, and decreased appetite.  No risk is mentioned in 100% of 
Wellbutrins unique ads, however in 87.5% they list seizure/ tremor, dry mouth, insomnia, 
and increased blood pressure. Other side effects are mentioned with varying percentages. 
Overall, as mentioned before, Effexor (XR) mentions more risks than any other 
brand by a significant margin.  Zoloft, even though it has the greatest number of unique 
advertisements, only mentions risks with the second highest frequency.   The risks 
mentioned most frequently are sleep related side effects (insomnia and drowsiness/ 
sleepiness/ yawn), gastrointestinal side effects (diarrhea/ constipation/ upset stomach, 
nausea, and dry mouth) as well as the sexual side effect of impairment.  Paxil is the only 
brand to mention the general health risks of injury/ trauma, vision impairment, infection 
as well as decreased appetite.  The Wellbutrin types are the only brand to mention sore 
throat. 
 
4. Type of appeal used in the advertisement: 
In order to examine the type of appeal utilized in the advertisements, I examined a 
number of different features of ad appeal.  The first thing I examined was the overall 
nature of the appeal.  Each unique ad was coded with one type of appeal representing the 
major or primary appeal used in the ad. They occurred with the following frequencies: 
75 
 
TABLE 10: OVERALL AD APPEAL BY BRAND 
 
 
The overall ad appeal used most frequently is motivational.  This appeal is 
utilized in order to motivate people to self-diagnosis and therefore desire medication.  
This, of course, would lead to an increase in sales.  This appeal is used by Effexor (XR) 
in 83.33% of their 18 unique ads, Prozac in 100% of their 15 unique ads, and Paxil in 
33.33% of their 3 unique ads.  An anecdotal/testimonial appeal is utilized by the 
Wellbutrins in 62.5% of their unique ads and in 17.39% of Zoloft’s 23 unique 
advertisements.  This is used by these brands in order to make the reader feel less 
stigmatized and that to be able to relate to the person featured in the ad.  Popular appeals 
(only used by Effexor in 16.67% of their unique ads) attempt to do a similar thing; they 
want the reader to feel as if they are not alone in their suffering.  As mentioned earlier, 
Wellbutrin SR is the only brand that contains an ad that has a solely promotional appeal.  
Zoloft is the only brand that utilizes an informative appeal in 82.61% of their unique 
ads.  The Wellbutrins are the only brands that emphasize safety, the low risk of certain 
 Celexa 
 
N = 1 
Serzone
 
N = 1 
Effexor 
(XR) 
N = 18 
Prozac
 
N = 15 
Paxil 
CR 
N =3
Wellbutrin 
SR & XL 
N = 8 
Zoloft
 
N =23
Total
Anecdotal/ 
Testimonial 
0 0 0 0 0 5 4 9 
Motivational 0 0 15 15 1 0 0 31 
Promotional 0 0 0 0 0 1 0 1 
Emotional 1 1 0 0 2 0 0 4 
Popular 
Appeal 
0 0 3 0 0 0 0 3 
Safety 0 0 0 0 0 2 0 2 
Informative 0 0 0 0 0 0 19 19 
TOTAL 1 1 18 15 3 8 23  
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side effects, in their advertisements and do so in 25% of their unique ads. 
 
The next dimension of appeal I measure was the specific targeting techniques used 
in the ad.  First is the use of people in the advertisements.   These are the frequencies with 
which the ads feature pictures of people.  Of the ads that include more than one person, 
there is always one person that can be considered the “primary” person.  This signifies 
that either: they are the one clearly in the grips of depression and have/will be utilizing 
antidepressant medication; or that they are the person featured in the forefront of the 
advertisement and the consumer would be more likely to focus their attention on this 
individual.  The Table 11 also shows the frequencies of the primary person’s race, gender 
and age for the 34 unique ads that featured people. 
TABLE 11: APPEARANCE OF PEOPLE BY BRAND 
 
 
 
 
 
 
 
 Celexa 
 
N = 1 
Serzone
 
N = 1 
Effexor 
(XR) 
N = 18 
Prozac
 
N = 15 
Paxil 
CR 
N =3 
Wellbutrin 
SR & XL 
N = 8 
Zoloft
 
N =23
Total
0 people 0 0 0 15 0 1 19 35 
1 person 1 1 3 0 1 4 0 10 
2 people 0 0 15 0 0 3 2 20 
3 people 0 0 0 0 2 0 2 4 
TOTAL 1 1 18 15 3 8 23 69 
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CHARACTERISTICS OF PRIMARY PERSON  
 
 
There are undeniable differences in how the different brands utilize people in their 
advertisements.  Both Celexa and Serzone use one white, adult female in their singe 
unique ads, as does Wellbutrin SR in its unique ad that is not promotional.  Effexor 
(XR) uses people in 100%l of its 18 unique advertisements- and again, these people are 
white, adult, and female.  Paxil CR’s unique ads contain people that are men, women 
and children; again they are all clearly identified as Caucasian.    It is important to note 
that though men and children are also featured in some of the Paxil CR ads, it is always 
the woman that is portrayed as being in the grips of depression (refer to Figure 6). 
Prozac does not feature people in any of their fifteen unique advertisements.  People are 
featured in 87.5% of Wellbutrin’s unique advertisements.  They all contain white adults; 
no gender is specified because a man and woman are both equally featured.  
 Celexa 
 
N = 1 
Serzone
 
N = 1 
Effexor(XR)
 
N = 18 
Paxil CR
 
N =3 
Wellbutrin 
SR & XL 
N = 7 
Zoloft
 
N =4 
Total 
RACE  
White 1 1 18 3 7 2 32 
Black 0 0 0 0 0 1 1 
Asian 0 0 0 0 0 1 1 
GENDER  
Male  0 0 0 0 - 0 0 
Female 1 1 18 3 - 4 27 
AGE  
Adult 1 1 0 3 7 4 16 
Child 0 0 0 0 0 0 0 
Teen 0 0 0 0 0 0 0 
Elder 0 0 0 0 0 0 0 
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FIGURE 13 
EXAMPLE OF AD WITH EQUAL GENDER FOCUS 
Wellbutrin XL ad (U.S. News and World Report, February 28th, 2005)  
 
Zoloft is unlike any other brand in that in the 17.39% of their unique ads that show 
people, they feature black, white and Asian men, women, and children. (Figure 14) 
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FIGURE 14 
EXAMPLE OF AD FEAUTRING AFRICAN-AMERICANS: 
Zoloft ad (Essence, June 2003) 
 
 Therefore, only half of the unique advertisements feature people as part of the ad 
appeal.  100% of Prozac’s unique ads and 82.61% of Zoloft’s unique ads do not show 
people.  The other brands do so in 100% of their unique advertisements.  Zoloft is the 
only brand to feature African Americans and Asians and does so in 8.70% of their 
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unique ads.   Every other brand to feature people only show Caucasian adults 100% of 
the time.  
 Next is the area of subtle messaging techniques; the demeanor and social 
depiction of the people in the advertisements.  In Celexa’s one unique advertisement, the 
woman is featured alone but has a clear smile on her face.  In fact, this ad states, “What’s 
behind that smile?  Ask your doctor about treating depression with Celexa.”  It is clear 
that this smile is the result of the medication.  All three of Effexor’s unique ads feature 
white women in the grips of depression.  They are featured alone and have a sad/stern 
demeanor (refer to Figure 7).  The fifteen Effexor XR ads are all fairly similar except for 
slight differences such as a phone number.  They all feature one primary person (a white 
female) in three different stages (refer to Figure 15).  In the first, she is shown alone and 
clearly has a sad/stern demeanor.  The title underneath this picture is “Existing.”  Next, 
she is pictured with another white female, and she seems to have no particular expression.  
The caption under this says “Functioning.”  Lastly, it says “Back To Me.”  She is 
featured again with the white female, but now has a happy/smiling demeanor.  This 
shows the continuum of her first suffering from depression, then starting treatment, then 
finally getting back to her “old self.”   
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FIGURE 15 
EXAMPLE OF AD WITH BEFORE/AFTER CONTINUUM: 
Effexor XR ad (Good Housekeeping, July 2003) 
 
Paxil CR, as shown in Figure 6, illustrates a Caucasian woman in the grips of depression 
and is separated spatially from her husband and young son.  All three have a stern 
expression.  However, in the lower left hand corner of the advertisement, there is a 
picture of the same woman and her son together, and they are smiling and laughing.  It 
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clearly demonstrates that the medicine has reunited her with her son and helped her 
depression.   
 Wellbutrin’s unique advertisements (except for the one promotional Wellbutrin 
SR ad) feature people use two different subtle messaging techniques.  Both are used as a 
way to portray the benefit emphasized in all of these advertisements: that there is a low 
risk of sexual side effects.  The first is to feature a white adult female alone, but who is 
happy and smiling (Figure 15).   
 
FIGURE 16 
EXAMPLE OF SUBTLE MESSAGING TECHNIQUE: 
Wellbutrin SR ad (People, March 5th, 2001) 
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She is looking at herself in the mirror and the caption next to it says, “I’m feeling good.  
I’m taking once-a-day WELLBUTRIN XL (or SR), an antidepressant with a low risk of 
sexual side effects.”  The other is to feature a man and woman in a romantic setting who 
are both happy and smiling (Figure 16).  Again, the ad states that Wellbutrin XL has a 
low risk of sexual side effects.  This is one of only two unique ads that do not obviously 
portray a woman as the primary sufferer of depression.  Zoloft only features people in 
17.39% of their unique advertisements; these are all ads specifically targeted at treating 
PMDD.  They include people from different races and ages, but all featured with other 
people, happy and smiling (refer to Figure 13).   
 Overall, no particular subtle messaging technique is used more often than another.  
The visual appeals range from featuring a person depicting the “before” state of 
depression, the “after” state of depression once medication has been taken, and any state 
in the middle.  People are feature alone or with others.  The only visual appeal that is 
used with remarkable frequency across all the brands is the use of Caucasian, adult 
females in the advertisements.    
 
2.  Analysis of Results at the Frequency Level 
  The 69 unique ads appeared a total of 378 times in the sample magazines from 
1995-2005.  Ads from the seven brands occurred with the following frequencies: 
 
 
 
 
84 
 
TABLE 12:  AD APPEARACE BY BRAND 
BRAND MANUFACTURER N % 
CELEXA Forest Pharmaceuticals 1 0.26 
SERZONE Bristol-Myers Squibb Company 1 0.26 
EFFEXOR & EFFEXOR 
XR 
Wyeth Pharmaceuticals 53 14.02 
PROZAC Eli Lilly 87 23.02 
PAXIL CR GlaxoSmithKline 27 7.14 
WELLBUTRIN (SR & XL) GlaxoSmithKline 47 12.43 
ZOLOFT Pfizer 162 40.21 
TOTAL  378 100% 
 
The three brands with the greatest number of unique advertisements (Effexor and 
Effexor XR, Prozac, and Zoloft) were also the brands that had ads appearing with the 
greatest frequencies. In fact, Zoloft advertisements made up 40.21% of all antidepressant 
advertisements which appeared in the magazine data set.   Prozac advertisements made 
up nearly a quarter of all antidepressant ads, Effexor and Effexor XR made up 14.02% of 
all the ads.  It is clear that these three brands are the heaviest advertisers of antidepressant 
medication seen by consumers. Both Wellbutrin types constituted 12.43% and Paxil CR 
contributed to 7.14% of all antidepressant advertisements.   Celexa and Serzone each had 
only one ad appearance in my data set.  Therefore, for the remainder of my results, these 
two brands will be collapsed into one category of antidepressant titled “Other.”   
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AD APPEARNCE BY MAGAZINE CATEGORY 
As previously described, the magazines were organized into four different 
categories: Women’s magazines (Better Homes and Gardens, Good Housekeeping, TV 
Guide, Family Circle, McCalls-Rosies, and Woman’s Day), Young Adult magazines 
(Vogue, Cosmopolitan, and Glamour), African American magazines (Ebony and 
Essence), and General Interest magazines (Newsweek, People, Reader’s Digest, Sports 
Illustrated, Time, and U.S. News and World Report).  The ads were found in these 
magazines and occurred with the following frequencies:
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TABLE 13: AD APPEARANCE BY MAGAZINE 
 
MAGAZINE N % 
WOMEN’S 149 39.42 
Better Homes and Gardens 23 6.08 
Good Housekeeping 36 9.52 
T.V. Guide 19 5.03 
Family Circle 21 5.56 
McCalls-Rosies 10 2.65 
Woman’s Day 40 10.58 
YOUNG ADULT 50 13.23 
Vogue 10 2.65 
Cosmopolitan 11 2.91 
Glamour 29 7.67 
AFRICAN AMERICAN 20 5.29 
Ebony 9 2.38 
Essence 11 2.91 
GENERAL INTEREST 159 42.06 
Newsweek 14 3.70 
People 61 16.14 
Reader’s Digest 16 4.23 
Sports Illustrated 8 2.12 
Time 23 6.08 
U.S. News and World Report 37 9.79 
TOTAL 378 100.00 
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Clearly, the advertisements appeared with greater frequency in some magazines over 
others.  The magazines with the most appearances of antidepressant advertisements over 
this time period fall under the magazine categories of Women’s and General Interest.  
The magazines with the largest ad appearances are People (16.14%) and Woman’s Day 
(10.58%).  U.S. News and World Report and Good Housekeeping also have ads 
appearing with substantial frequencies (9.79% and 9.52%, respectively).  The other 
magazines each contain less than 8% of all antidepressant advertisement appearances.   
MAGAZINE CATEGORIES BY BRAND 
It is clear that the ads are appearing in certain magazines over others in order to 
reach a certain target market.  The next issue to investigate is which specific 
antidepressant brands are advertising in these magazine categories.  
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TABLE 14: AD APPEARANCE BY BRAND DISTRIBUTED BY MAGAZINE CATEGORY 
EFFEXOR & 
EFFEXOR 
XR 
PAXIL CR PROZAC WELLBUTRIN 
SR & XL  
ZOLOFT OTHER TOTAL  
N % N % N % N % N % N % N % 
WOMEN’S 25 47.17 6 22.22 19 21.84 15 65.96 83 51.23 1 50.00 149 39.42 
YOUNG 
ADULT 
0 0 6 22.22 17 19.54 1 2.12 25 15.43 1 50.00 50 13.23 
 
AFRICAN 
AMERICAN 
0 0 0 0 7 8.05 0 0 13 8.02 0 0 20 5.29 
GENERAL 
INTEREST 
28 52.83 15 55.56 44 50.57 31 31.91 41 25.31 0 0 159 42.06 
TOTAL 53 100 27 100 87 100 47 100 162 100 2 100 378 100 
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In analyzing ad appearance by brand distributed by magazine category, certain 
targeting trends become apparent.  The Effexors only target in Women’s and General 
Interest magazines and do so fairy equally, 47.17% and 52.83% respectively.  
GlaxoSmithKline, the manufacturer of Paxil CR and both Wellbutrins, advertised these 
two brands in Women’s, Young Adult, and General Interest magazines but not those 
targeted at African Americans.  The largest percentage of the ads for Paxil CR brand 
appeared in General Interest magazines (55.56%) and the largest percentage of the ads for 
the Wellbutrins appeared in Women’s magazines (65.96%).  The only brands that target 
African American magazines are Prozac and Zoloft.  However, they do not advertise 
equally across the magazine categories.  50.27% of Prozac’s ads appear in General 
Interest magazines, and 51.23% of Zoloft ads appear in Women’s magazines.  A mere 
8% of the ads for these two brands appear in African American magazines.  
Overall, the most advertisements for antidepressants appear in General Interest 
magazines; 42.06% of all the ads appear in this magazine category.  Women’s magazines 
have the second most antidepressant ad appearances following close behind General 
Interest magazines, totaling 39.42% of the advertisements.  13.23% of the ads appear in 
Young Adult magazines and only 5.29% appear in African American magazines.    
 
TIME TRENDS 
Another crucial aspect of any inspection of the antidepressant advertisement 
market is the years in which these ads appeared.   
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AD APPEARANCE BY YEAR 
The following is a graph of the frequency of ad appearance by year.   The brand 
names indicate when that respective brand was approved by the FDA.  Prozac, Zoloft, 
Effexor and Serzone were all approved prior to 1995, the date of the first ad appearance 
(they were approved in 1987, 1991, 1993 and 1994 respectively).   
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FIGURE 17 
AD APPEARNCE BY YEAR 
 
Before 1995, the date of the first ad appearance, four drugs in my data set were 
already on the market: Prozac, Zoloft, Effexor, and Serzone.  However, though these 
drugs already had FDA approval, strangely there are no ads appearing for these brands 
before this date.  Once the ads began to appear in 1995, they increased at a fairly steady 
rate until 1998.  During this four year period, three new drugs were introduced into the 
market: Wellbutrin SR, Effexor XR, and Celexa.  Then, the most interesting thing to note 
when looking at time trends of antidepressant advertisements occurs; there is a complete 
lack of ads that appear in my magazine data set during 1999 and 2000.  There are several 
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possible explanations for this occurrence.  As mentioned earlier, the FDA relaxed its 
regulatory requirements for DTC advertising on broadcast media in August 1997 (Calfee 
2001, FDA 1997). This decision triggered large increases in the volume of television 
DTC advertising while simultaneously prompting a shift from print to broadcast media. 
In August 1999, after a two-year review, the FDA reaffirmed its new policy, while also 
announcing its intention to review DTC advertising again in 2001 (FDA 1999a). 
Therefore, the lack of advertisements could be the combined effect of the switch to 
broadcast media advertising as well as the anticipation of FDA’s impending future DTC 
advertising review (Calfee, 2001).  Another possible explanation is that after market 
shares have been established and brand awareness achieved, DTC advertisement 
spending declines.  In 1999, among all antidepressants, only Paxil had some DTC 
advertisement spending (2.2% of sales), while Celexa, Effexor, Prozac, Serzone and 
Zoloft had no DTC advertisement spending (Berndt 228-9).  Also, Prozac’s advertising 
only ran from August 1997 to April 1998 (Grow et al, 171).  Since Prozac contributed to 
23.02% of all the advertisements in my data set, this cease could possibly contribute to 
the lack of ads in the two years after.   
After the deficiency of ads from 1999 to 2000, the ads increased somewhat 
steadily until 2003 when they reached their maximum.  In this year, 32.01% of all the ad 
appearances occurred.  For the remaining years in the data set, the frequencies of ads 
decrease at a steady rate.  One possible reason for this decline is that spending is much 
lower when a generic competitor to the brand is on the market.  This is due to the fact that 
the branded drugs may not be able to recoup the benefits from DTC advertisement 
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spending when generic competition exists.  The introduction of generic antidepressants 
occurred in the following years: 
TABLE 15: GENERIC ANTIDEPRESSANT APPROVALS 
GENERIC BRAND NAME DATE OF FDA 
APPROVAL 
Citalopram Celexa October 2004 
Nefazodone Serzone September 2003 
Venlafaxine Effexor August 2006 
Bupropion SR Wellbutrin SR January 2004 
Bupropion XL Wellbutrin XL December 2006 
Fluoxetine Prozac August 2001 
Sertraline Zoloft June 2006 
 
Since a majority of the generics were introduced from 2003 on, it is possible that this was 
part of the reason ads declined after this year.    In order to further understand what is 
driving the ups and downs of ad appearances, it is necessary to analyze the ads 
throughout this decade distributed by brand.  
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AD APPEARNCE BY YEAR DISTRUBTED BY BRAND 
 
There are clear trends in analyzing what brands advertised in each year, especially 
the four brands with the greatest ad appearances: Effexor (XR), Prozac, Wellbutrin (SR 
and XL), and Zoloft.  The increase in ads from 1995 to 1998 was driven mostly by the 
appearance of Prozac advertisements.  Eli Lilly, the maker of Prozac, was the first 
pharmaceutical manufacturer to begin DTC advertising for antidepressants.  They were 
also the first to cease advertising (probably due to Prozac’s impending patent expiration) 
(Grow et al, 2006).  Though Paxil is not included in Figure 18, it is important to note that 
this brand did have sporadic ad placement in 1999-2001, but none of these ads appeared 
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in the magazines in my data set.  They did, however, have extensive placement in 2002 in 
which my magazines featured 12 Paxil CR ads.  The small spike in 2001 can be 
contributed mostly to Zoloft; this is the year Pfizer began running advertisements for its 
Zoloft brand.  Thirty advertisements appeared in this year, and 83.33% were for this 
antidepressant.  Zoloft continues to drive the increase in advertisements following 2002 
in addition to growth in both Effexor XR and Wellbutrin XL ads.   The same brands seem 
to be responsible for the subsequent decline in ad appearance thereafter.  Therefore, it 
becomes clear that what brands advertised in what year drive any discernable trends.  
Specifically, Effexor (XR), Prozac, Wellbutrin (SR and XL), and Zoloft are the brands 
that consumers will see most often in antidepressant advertisements.  Which specific 
brand is seen most prevalently depends on the year (see Appendix 3).  
 
Causes of Depression 
The frequencies with which the following statements regarding the causes of 
depression are made in the advertisements are: 
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TABLE 16: APPEARANCE OF CAUSES 
CAUSE N % 
Biochemical/ Medical Causes   
“When you’re clinically depressed the level of serotonin may drop.”  55 14.55 
“Depression could be caused by a chemical imbalance.” 142 37.57 
“PMDD is related to hormonal changes and chemicals in your body.” 39 10.32 
Personal Causes 
“It can be triggered by stressful life, or it can appear suddenly.” 74 19.58 
Causes are Unspecified/ Unknown 
“Depression is a real illness with real causes. 107 28.31 
“The cause of depression is unknown.” 100 26.46 
No causes identified 31 8.21 
** multiple causes may be identified in a single advertisement, therefore percentages do not add up to 100.00% 
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91.79% of all ads had some statement concerning the causes of depression.  There 
are three major messages regarding these causes that are reaching the consumer through 
antidepressant advertisements.  First, is that depression is a real illness with real causes; 
this appears in 28.31% of all ad messages.   It can be inferred that antidepressant 
manufacturers would want consumers to understand depression as a real disease as 
opposed to a merely a “mood” because then it would be logical and reasonable to take 
medication.  The next prevalent message, however, is that the cause of depression is 
unknown.  This is stated in a quarter of all the ad appearances, 26.46%.    Lastly, as I had 
hypothesized, 37.57% of all ads stated that depression could be caused by a chemical 
imbalance.  This is the statement regarding causes that is made most frequently in all of 
the advertisements.   
Only 8.21% of the ads identify no causes of depression.  Therefore, the majority 
of advertisements educate consumers about the causes of depression to some degree.  As 
for mentioning personal causes of depression, statements like this appeared in 19.58% of 
all advertisements.  Therefore, this type of cause was mentioned with substantial 
frequency is not a prevalent message seen by consumers.   
Next, I analyzed how the causes of depression are portrayed to the consumer differ by 
what magazine category the ad appeared in.   
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TABLE 17: MAGAZINE CATEGORIES DISTRIBUTED BY APPEARANCE OF CAUSES 
WOMEN’S YOUNG ADULT AFRICAN 
AMERICAN 
GENERAL 
INTEREST 
CAUSE 
N= 149 % N=50 % N=20 % N=159 % 
Biochemical/ Medical Causes 
“When you’re clinically depressed the 
level of serotonin may drop.”  
11 7.38 11 22.00 4 20.00 29 18.24 
“Depression could be caused by a 
chemical imbalance.” 
61 40.94 22 44.00 11 55.00 48 30.19 
“PMDD is related to hormonal changes 
and chemicals in your body.” 
20 13.42 8 16.00 4 20.00 7 4.40 
Personal Causes 
“It can be triggered by stressful life, or it 
can appear suddenly.” 
16 10.74 13 26.00 5 25.00 40 25.16 
Causes are Unspecified/ Unknown 
“Depression is a real illness with real 
causes. 
22 14.77 17 34.00 7 35.00 61 38.36 
“The cause of depression is unknown.” 52 34.90 11 22.00 9 45.00 28 17.61 
 ** multiple causes may be identified in a single advertisement, therefore percentages do not add up to 100.00% 
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 Of the 149 advertisements that appeared in woman’s magazines, the majority of 
the statements regarding the causes of depression are that it could be caused by a 
chemical imbalance (40.94%), or that the causes are unknown (34.90%).  Therefore, 
these are the messages reaching the readers of woman’s magazines with the greatest 
frequency.  In fact, woman’s magazines infrequently mention anything regarding 
personal causes of depression.  Only a small percentage of ads, 10.74, claim that the 
causes of depression can be triggered by a stressful life, or that depression can appear 
suddenly.  In young adult magazines, similarly to woman’s magazines, the chemical 
imbalance cause of depression is also mentioned in the largest percentage of the 50 ads; 
44.00%.  However, the ads that appear in young adult magazines also state that 
depression is a real illness with real causes 34.00% of the time.  In magazines targeted to 
African Americans, more than half of the antidepressant advertisements (55.00%) claim 
that depression could be caused by a chemical imbalance.  This magazine category has 
the highest percentage of its ads, more than any other magazines category, making this 
biochemical/medical statement.  African American magazines also have the greatest 
percentage of their ads stating that the cause of depression is unknown (45.00%).  
General interest magazines are the only magazine category that doesn’t have the highest 
percentage of its ads stating that depression could be caused by a chemical imbalance, 
though this is still stated in 30.19% of its ads.  The most prevalent statement in these ads 
is that depression is a real illness with real causes; this appears in 38.46% of all general 
interest ads.  This magazine category also has the lowest percentage mentioning that 
PMDD is related to hormonal changes and chemicals in your body.  This could possibly 
be due to the fact that these magazines have both a male and female readership.  
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In analyzing the causes of depression and how they are distributed across 
magazine category, it is clear that some causes are listed more frequently in certain 
magazine categories over others.  There are three biochemical/medical causes, and each 
is used with varying frequency in the different magazine categories.  “when you’re 
clinically depressed the level of serotonin may drop” is mentioned most frequently in 
general interest magazines and is mentioned equally in both woman and young adult 
magazines.  Claiming that depression is, more generally, caused by a chemical 
imbalance, is mentioned with the most frequency in women’s magazines.  Claims 
regarding PMDD are used more substantially in woman’s magazines than any other 
magazine category.   
The magazine category that includes the highest frequency of ads that mention 
personal causes of depression such as a stressful life is young adult magazines.  In fact, 
personal causes are mentioned in about a quarter of the ads for every magazine category 
except for women’s magazines (where they are only mentioned in 10.74% of ads).  The 
same holds true for saying that depression is a real illness with real causes.  This 
statement is made with fairly equivocal percentages within every magazine category 
except for Women’s magazines where it is mentioned half as frequently (in only 14.77% 
of the ads).  Stating that the cause of depression is unknown is mentioned most frequently 
in African American magazines (45.00%).     
 
 Self-Diagnosis 
The frequencies of how many ads include the following symptoms of depression are:  
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TABLE 18: SELF-DIAGNOSIS: SYMPTOMS OF DEPRESSION 
**multiple symptoms may be identified in a single advertisement, therefore percentages do not add   up to 
100.00% 
 
The symptoms of depression mentioned most often in antidepressant ads are 
fatigue/low energy (55.56%), depression/sadness (55.29%), and agitation/irritability 
(46.03%).  The next most prevalent symptoms are a loss of interest (38.62%) and 
everyday life being unbearable (35.45%).   Approximately 28% of the ads mention an 
inability to concentrate, change in sleep patterns, and change in appetite.  High stress and 
anxiety is a symptom mentioned in 17.99% of ads and the obvious symptom of sadness 
(that lasts weeks) appears in 6.61% of ads.  The symptoms of depression that appear with 
the lowest frequency are thoughts of death/suicide (6.61%) and restlessness (5.56%).  
SYMPTOMS N = 378 % 
SEVERELY 
PSYCHOLOGICAL 
  
Everyday life unbearable 134 35.45 
Thoughts of Death/ Suicide 25 6.61 
PHYSICAL/ 
PSYCHOLOGICAL 
  
Inability to Concentrate 108 28.57 
Loss of Interest 146 38.62 
High Stress/Anxiety 68 17.99 
PHYSICAL ACTIVITY 
CHANGE 
  
Change in Sleep Patterns 108 28.57 
Change in appetite 109 28.84 
Fatigue/Low energy 210 55.56 
DEPRESSIVE SYMPTOMS   
Depression/ Sadness 209 55.29 
Sadness lasts weeks 25 6.61 
OTHER   
Agitation/ irritability 174 46.03 
Restlessness 21 5.56 
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The low frequency of mentioning thoughts of death or suicide might be because of its 
severity and seriousness.  The low frequency of restlessness might be because it could be 
considered a subcategory of agitation/irritability or inability to concentrate.    
Overall, the most prevalently mentioned symptoms fall under various categories.  
No one category of symptoms appears substantially more than any other category.  By 
providing the reader with a wide range of symptoms, there is a much greater chance for 
self-diagnosis.   
Next, I analyzed the appearance of symptoms of depression by magazine 
category.
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TABLE 19:  MAGAZINE CATEGORIES DISTRIBUTED BY SYMPTOMS OF DEPRESSION 
 
 WOMEN’S YOUNG ADULT AFRICAN 
AMERICAN 
GENERAL INTEREST 
SYMPTOMS N= 149 % N=50 % N=20 % N=159 % 
SEVERELY 
PSYCHOLOGICAL 
 
Everyday life unbearable 45 30.20 20 40.00 8 40.00 61 38.36 
Thoughts of Death/ Suicide 6 4.03 1 2.00 0 0 18 11.32 
PHYSICAL/ 
PSYCHOLOGICAL 
 
Inability to Concentrate 26 17.45 23 46.00 7 35.00 52 32.70 
Loss of Interest 65 43.62 15 30.00 6 30.00 60 37.74 
High Stress/Anxiety 31 20.81 9 18.00 6 30.00 22 13.84 
PHYSICAL ACTIVITY 
CHANGE 
Change in Sleep Patterns 50 33.56 24 48.00 7 35.00 84 52.83 
Change in appetite 24 16.11 17 34.00 7 35.00 61 38.36 
Fatigue/Low energy 80 53.69 27 54.00 11 55.00 92 57.86 
DEPRESSIVE 
SYMPTOMS 
 
Depression/ Sadness 86 57.72 31 62.00 13 65.00 79 49.69 
Sadness lasts weeks 5 3.36 2 4.00 0 0 18 11.32 
 
OTHER 
 
Agitation/ irritability 59 39.60 34 68.00 13 65.00 68 42.77 
Restlessness 6 4.03 6 12.00 0 0 9 5.66 
**multiple symptoms may be identified in a single advertisement, therefore percentages do not add up to 100.00%
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The symptoms that occur most often occur in women’s magazines are fatigue/ 
low energy (53.69%) and depression/ sadness (57.72%).  In young adult magazines the 
most reoccurring symptoms of depression that are listed are, similar to woman’s 
magazines, depression/ sadness (62.00%) in addition to agitation/ irritability (68.00%).  
Interestingly, antidepressant ads in African-American magazines are most likely to list 
the same two symptoms of depression as in young adult magazines; depression/ sadness 
and agitation/irritability.  Both appear in 65.00% of ads in this magazine category.. In 
general readership magazines, the most frequently referred to symptoms are change in 
sleep patterns (52.83%) and fatigue/ low energy (57.86%).  As in every other magazine 
category, depression/sadness is also referred to in a large portion of the advertisements 
(49.69%). 
 Overall, after running this analysis (Table 19), there seems to be no apparent 
trends regarding which symptoms are listed in what magazine category.  Depression/ 
sadness seems to be mentioned frequently in every magazine category, as is fatigue/ low 
energy.  Physical/ psychological symptoms as well as symptoms involving physical 
activity changes are mentioned with substantial frequency within all magazine types.  
Thoughts of death and suicide and restlessness are rarely mentioned in any of the 
magazine categories and are never mentioned in African American magazines.     
I also analyzed whether the symptoms are presented in a quiz or checklist format.   
TABLE 20:  SELF-DIAGNOSIS: PRESENTATION OF SYMPTOMS 
PRESENTATION OF 
SYMPTOMS 
N = 378 % 
QUIZ FORMAT 44 11.64 
CHECKLIST FORMAT 21 5.56 
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A questionnaire or quiz regarding one’s symptoms occurred 44 times, in only 
11.64% of the total ads.  A checklist of symptoms appeared 21 times in only 5.56% of the 
ads.  Therefore, though this tactic is used, it does not appear with a remarkable frequency 
and therefore probably does not contribute substantially to self-diagnosis. 
In addition, I noted with what frequency the ads provide a phone number, website, or 
free information/booklets.   
TABLE 21:  SELF-DIAGNOSIS: FURTHER CONTACT INFORMATION 
FURTHER CONTACT 
INFORMATION 
N = 378 % 
PHONE NUMBER 272 71.96 
WEBSITE 321 84.92 
FREE INFORMATION/ 
BOOKLET 
8 2.12 
ASK/NOTIFY/ SEE YOUR 
DOCTOR 
377 99.74 
The frequency of ads that provided a phone number was 272, or in 71.96% of the 
ads.  321 times an ad appeared that provided a website; totaling 84.92% of the ads.  
Therefore a majority of advertisements provide the reader with further contact 
information.  Free information or booklets was a tactic used much more infrequently.  It 
was only offered 8 times for a total of 2.12% of the ads.  Clearly, this is not a popular 
offering used by the brand manufacturers.  The last aspect of self-diagnosis I analyzed is 
whether the ads specifically state to “ask/notify/see your doctor.”  This occurred in every 
ad but one (the promotional ad) for a total of 377 times or in 99.74% of the ads.     It is 
clear that this is the most frequent message in antidepressant advertisements and is 
utilized by every manufacturer.  This is not surprising considering that a patient must be 
prescribed a prescription drug from a doctor.    
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 The features of self-diagnosis were analyzed in terms of what magazines category 
they appeared in.  Checklists only appear in ads featured in women’s magazines (2.68%) 
or in general interest magazines (10.69%). Quiz/questionnaires mainly appear in the same 
magazines; in 18.22% of Women’s magazines and in 9.43% of General Interest 
magazines.  Free information or booklets are never offered in magazines categorized as 
African-American, but are offered in 8.01% of ads in Young Adult magazines, in 2.01% 
of Women’s magazines and in 1 ad in a General Interest magazine (0.63%).  A 
recommendation to ask/notify/see your doctor appears in all types of magazines.   
 
Benefits and Risks 
 I analyzed the frequency with which both benefits and risks are mentioned in 
antidepressant advertisements.   
TABLE 22: BENEFITS OF MEDICATION 
** multiple benefits may be claimed within a single advertisement, therefore percentages do not add up to 
100.00% 
BENEFITS N % 
General Health 
Works to correct chemical imbalance  132 34.92 
Reproductive Health 
Treats Pre Menstrual Dysphonic Disorder 39 10.32 
Psychological Health 
Product helps treat Post Traumatic Stress Syndrome 9 2.38 
Won’t change your personality 85 22.49 
General Claim 
Low occurrence of side-effects/ not usually serious/ well 
tolerated 
193 51.06 
Not habit forming 115 30.42 
Not associated with weight gain 27 7.14 
Convenient 38 10.05 
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The benefits most frequently stated in antidepressant ads are general product 
claims such that there is a low occurrence of side-effects, that these side effects are not 
usually seriously and they are well tolerated (51.06%).  Other benefits frequently claimed 
in these ads fall under general health: that these drugs work correct chemical imbalances 
(34.92%).  This benefit is most likely mentioned in connection to the cause that 
depression is caused by a chemical imbalance.  The next most prevalent benefit 
mentioned is that the medication is not habit forming (30.42%) and that it won’t change 
one’s personality (22.49%).  The reproductive health claim that the medication treats 
PMDD and the general health claim that it is convenient each appear in about 10% of 
ads.  The benefits mentioned the most infrequently are that it is not associated with 
weight gain (7.14%) and that the product helps to treat Post Traumatic Stress Syndrome, 
in 2.38% of ads. 
Next, I analyzed which benefits appeared in each magazine category. 
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TABLE 23:  MAGAZINE CATEGORIES DISTRIBUTED BY BENEFITS 
WOMEN’S YOUNG 
ADULT 
AFRICAN 
AMERICAN 
GENERAL 
INTEREST 
 
N % N % N % N % 
BENEFITS 
General Health 
Works to correct chemical 
imbalance  
73 48.99 11 22.00 9 45.00 39 24.53
Reproductive Health 
Treats Pre Menstrual 
Dysphonic Disorder 
20 13.42 8 16.00 4 20.00 7 4.40 
Psychological Health 
Product helps treat Post 
Traumatic Stress Syndrome 
5 3.36 0 0 0 0 4 2.52 
Won’t change your 
personality 
19 12.75 18 36.00 7 35.00 41 25.79
General Claim 
Low occurrence of side-
effects/ not usually serious/ 
well tolerated 
64 42.95 40 80.00 12 60.00 77 48.43
Not habit forming 53 35.57 20 40.00 6 30.00 36 22.64
Not associated with weight 
gain 
13 8.72 7 14.00 0 0 7 4.40 
Convenient 11 7.38 0 0 0 0 27 16.98
** multiple benefits may be claimed within a single advertisement, therefore percentages do not add up to 
100.00% 
In woman’s magazines, the benefit most frequently referred to (in 48.99% of the 
ads) is the general health benefit that it works to correct a chemical imbalance.  In 
42.95% of the ads in woman’s magazines, it also claims the benefit that there is a low 
occurrence of side-effects/ not usually serious/ well tolerated.  Reproductive health 
claims and psychological health claims are mentioned with varying frequencies, but none 
occur in more than 14% of ads.  In young adult magazines, the benefits most frequently 
mentioned are general claims: that there is a low occurrence of side-effects/ not usually 
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serious/ well tolerated (80% of ads), and that the medication is not habit forming (40% of 
ads).  The medication being convenient is not mentioned in any of the ads appearing in 
young adult magazines (the medication being convenient is only mentioned in women’s 
and general interest magazines), and neither is the psychological health claim that the 
product helps to treat Post Traumatic Stress Syndrome.  In fact, these three benefits in 
addition to not being associated with weight gain are also not mentioned in any 
advertisements in African American magazines.  Antidepressant ads in African-American 
magazines tend not to list a number of both benefits and risks.  The benefit that is most 
frequently mentioned is that there is a low occurrence of side-effects/ not usually serious 
/well tolerated.  This claim appears in 60% of all antidepressant ads in African-American 
magazines.  As for general interest magazines, all the benefits are mentioned with 
varying degrees, with the one mentioned most frequently being that there is a low 
occurrence of side-effects/ not usually serious /well tolerated.   
 The frequency of risks are as follows:
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The category of risks that has the greatest appearances within the advertisements 
is gastrointestinal risks, even though only four risks are included in this category.  These 
four side-effects are mentioned a total of 906 times in the advertisements, 32.98% of all 
benefits mentioned.   The next category with the most prevalence is sleep related side 
effects (24.40% of all benefits mentioned).  Only two risks are included in this group; 
 
TABLE 24:  RISKS OF MEDICATION 
RISKS N % 
General Health 552 20.23 
Sweating  120 31.75 
Dizziness/ lightheadedness 96 25.40 
Headaches 93 24.60 
Rash 87 23.02 
Seizure/tremor 68 17.99 
Lack of energy/ weakness 29 7.67 
Injury/ trauma 26 6.88 
Vision impairment 26 6.88 
Infection 7 1.85 
Gastrointestinal 900 32.98 
Diarrhea, constipation, upset stomach 331 87.57 
Nausea 290 76.72 
Dry mouth 270 71.43 
Sore throat 15 3.97 
Sleep Related 666 24.40 
Insomnia 335 88.62 
Drowsiness/ sleepiness/ yawn 331 87.57 
Sexual Side Effects 240 8.79 
Sexual impairment 240 63.49 
Psychological 177 6.49 
Anxiety/ nervousness/ agitation 138 36.51 
Suicidal thoughts/ action 32 8.47 
Decreased appetite 7 1.87 
Weight Effects 95 3.48 
Weight changes/anorexia 95 25.13 
Cardiovascular 99 3.63 
Increased blood pressure 99 26.19 
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insomnia and drowsiness/ sleepiness/ yawn; they both appear a total of 666 times.  In 
terms of individual risks, the ones most frequently listed in antidepressant ads are 
insomnia (88.62%)  and drowsiness/ sleepiness/ yawn  (82.57%).  Sexual impairment is 
also a risk in a total of 63.49% of the ads reaching the consumer.  The gastriointestinal 
risks of diarrhea/constipation/upset stomach (82.57%) and nausua (76.72%) are also 
frequently mentioned in the ads.   Next, I analyzed which risks appeared in each 
magazine category. 
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TABLE 25:  MAGAZINE CATEGORIES DISTRIBUTED BY RISKS 
WOMEN’S YOUNG 
ADULT 
AFRICAN 
AMERICAN 
GENERAL 
INTEREST
 
N % N % N % N % 
RISKS 
General Health 
Sweating  52 34.90 14 28.00 4 20.00 50 31.45 
Dizziness/ 
lightheadedness 
33 22.15 8 16.00 0 0 55 34.59 
Headaches 19 12.75 17 34.00 7 35.00 50 31.45 
Rash 19 12.75 17 34.00 7 35.00 44 27.67 
Seizure/tremor 22 14.77 7 14.00 0 0 39 24.53 
Lack of energy/ weakness 5 3.36 1 2.00 0 0 23 14.47 
Injury/ trauma 5 3.36 6 12.00 0 0 15 9.43 
Vision impairment 5 3.36 6 12.00 0 0 15 9.43 
Infection 1 0.67 0 0 0 0 6 3.77 
Gastrointestinal 
Diarrhea, constipation, 
upset stomach 
134 89.93 49 98.00 20 100.00 128 80.50 
Nausea 130 87.25 33 66.00 13 65.00 114 71.70 
Dry mouth 125 83.89 27 54.00 13 65.00 105 66.04 
Sore throat 2 1.34 1 2.00 0 0 12 7.55 
Sleep Related 
Insomnia 140 93.96 43 86.00 20 100.00 132 83.02 
Drowsiness/ sleepiness/ 
yawn 
134 89.93 49 98.00 20 100.00 128 80.50 
Sexual Side Effects 
Sexual impairment 112 75.17 31 62.00 13 65.00 84 52.83 
Psychological 
Anxiety/ nervousness/ 
agitation 
43 28.86 16 32.00 5 25.00 74 46.54 
Suicidal thoughts/ action 13 8.72 7 14.00 0 0 12 7.55 
Decreased appetite 1 0.67 0 0 0 0 6 3.77 
Weight Effects 
Weight changes/ anorexia 38 25.50 1 2.00 0 0 56 35.22 
Cardiovascular 
Increased blood pressure 40 26.85 1 2.00 0 0 58 36.48 
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In terms of risks, gastrointestinal, sleep related, and sexual side effects are 
mentioned with the most frequency overall. The risk mentioned the most in woman’s 
magazines is insomnia- this is mentioned in 93.96 of all ads that appeared in this 
magazine category.  In young adult magazines, 98% of antidepressant advertisements 
mention the risk of diarrhea/ constipation/ upset stomach as well as 
drowsiness/sleepiness/yawn.  These ads never mention the risk of infection and decreased 
appetite as ads in woman’s and general interest magazines do.  Antidepressant 
advertisements in African-American magazines mention the least number of risks.  Every 
single ad states the risk of diarrhea/ constipation/ upset stomach, insomnia, and 
drowsiness/sleepiness/ yawn.  A majority (65%) also mention nausea, dry mouth, and 
sexual impairment.  However none of the ads in this magazine category mention any kind 
of weight effects or cardiovascular risks.  General interest magazines mention all of the 
risks with varying frequencies.  The ones mentioned most often are insomnia (83.02%), 
diarrhea/constipation/upset stomach and drowsiness/sleepiness/yawn (both 80.50%).   
 
Type of appeal used in the advertisement: 
The frequency with which each major ad appeal appeared is as follows: 
TABLE 26: OVERALL NATURE OF AD APPEAL 
 N % 
ANECDOTAL/TESTIMONIAL 61 16.13 
MOTIVATIONAL 125 33.07 
PROMOTIONAL 1 0.26 
EMOTIONAL 23 6.08 
POPULAR APPEAL 21 5.56 
SAFETY 8 2.12 
INFORMATIVE 139 36.77 
TOTAL 378 100.00 
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 The largest percentage of ads uses an informative appeal.  It has been argued that 
the purpose of DTC advertising should be to educate the consumer.  A total of 36.77% of 
advertisements do so.  The other most popular overall ad appeal is motivational.  33.07% 
of ads use a motivational appeal and therefore a large portion of the ads that consumers 
see encourage them to take antidepressant medication.  It can be inferred that 
manufacturers utilize this appeal in order to increase sales.  The other popular ad appeal 
is anecdotal/motivational (16.33%).  Emotional and popular appeals are used quite 
infrequently; 6.08% and 5.56% respectively.  Safety and promotional appeals are rarely 
used.  Only 2.12% of ads use a safety appeal and only one ad (0.26%) uses a promotional 
appeal. 
 
MAGAZINE CATEGORIES DISTRIBUTED BY OVERALL NATURE OF AD 
APPEAL 
I ran this analysis, and the overall ad appeal does not vary substantially by 
magazine category.   
 
SPECIFIC TARGETING TECHNIQUES 
TABLE 27:  APPEARANCE OF PEOPLE IN ADVERTISEMENTS 
 N % 
0 PEOPLE 211 55.82 
1 PERSON 60 15.87 
2 PEOPLE 43 11.38 
3 PEOPLE 64 16.93 
TOTAL 378 100 
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 The majority of advertisements the consumer sees actually do not contain pictures 
of people.  A total 55.82% of these ads include only text, pictures, or anthropomorphic 
characters.  The remaining advertisements contain one, two, or three people; each appears 
with relatively the same frequency.  16.93% of ads contain three people, 15.87% of ads 
contain one person, and 11.38% of ads contain two people.  
 
MAGAZINE CATEGORIES DISTRIBUTED BY APPEARANCE OF PEOPLE 
I ran this analysis, and there were no significant trends.   
 
Of the ads that include more than one person, there is always one person that can 
be considered the “primary” person as discussed earlier.  This primary person has a race, 
gender, and age as follows:   
 
TABLE 28:  CHARACTERISTICS OF PRIMARY PERSON 
 
 N % 
RACE 
White 156 93.41 
Black 4 2.39 
Asian 7 4.19 
GENDER    
Male 0 0 
Female 156 93.41 
AGE 
Adult 167 100.00 
Child 0 0 
Teen 0 0 
Elder 0 0 
TOTAL 167 100.00 
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 There are obvious disparities in regards to the races, gender, and ages of people 
featured in antidepressant advertisements.  Out of the 167 advertisements featuring 
people, an overwhelming 93.41% of these advertisements feature Caucasian people.  In 
fact, in these advertisements, all of the people in the ads (not only the primary person) are 
white.  Only 2.39% and 4.19% of the ads feature a primary person who is African-
American or Asian, respectively.  When looking at gender, again there is an 
overwhelming disparity within the advertisements.  A remarkable 93.41% of the 
advertisements feature the primary person as a female.  The only two unique ads (that 
appeared eleven times) that were not included were because there is no obvious primary 
person.  It equally features both a male and female white adult (refer to Figure 13).  All of 
the ads with people featured an adult as the primary person.   
 
MAGAZINE CATEGORIES DISTRIBUTED BY CHARACTERISITCS OF 
PRIMARY PERSON 
WOMEN’S YOUNG 
ADULT 
AFRICAN-
AMERICAN 
GENERAL 
INTEREST 
 
N % N % N % N % 
RACE 
White 67 100.00 12 75.00 0 0 77 96.25 
African- 
American 
0 0 0 0 4 100.00 0 0 
Asian 0 0 4 25.00 0 0 3 3.75 
 
 All of the ads in woman’s magazines contain white people.  In young adult 
magazines, the majority of ads also feature white people, but 25% do feature an Asian 
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woman as the primary person.  African –American magazines feature black people in 
100% of their advertisements; this is the only magazine category to do so.  Asian people 
are also featured in general interest magazines, but this only occurs in 3.75% of the ads.  
Therefore, entire races of people are excluded from advertisements appearing in all  
magazine categories.  Though it seems reasonable that only African Americans are 
featured in that magazine category, black individuals are completely missing from 
antidepressant advertisements in every other magazine category.  In addition, Asian 
females reading Women’s magazines would fail to see any people of their own race in 
this magazine category.   
SUBTLE MESSAGING TECHNIQUES 
 The last aspect of subtle messaging techniques I analyzed is the demeanor and 
social depiction of people in the advertisements.  Of the 44.18% of the advertisements 
that contained people, there are three different methods of portraying them.  No one 
technique is used substantially more than any other.   The first method is to show the 
“primary person” in the grips of depression- alone and sad.  This occurred in a total of 
12.57% of the advertisements.  The second is to feature the “primary person” in an 
elevated mood, happy and smiling.  This occurs in a total of 55.69% of the ads.  It can be 
inferred that this person is in a positive mood due to the antidepressant medication.  This 
individual can be featured alone (23.35%) or with others (32.34%).  The last method is to 
show a set of before and after pictures.  This means that the ad will first show someone 
sad and alone suffering from the symptoms of depression.  Then, it will show a 
transformation where the person after medication becomes happy, smiling, and sociable 
(Figure 6).  This method is utilized in 31.74% of the ads.    
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B. Analysis 
1. Causes of Depression 
 One of the major benefits of DTC advertising is to increase awareness about 
diseases and treatment options.  Therefore, one goal of the ads is to educate readers about 
depression, specifically regarding the causes of this disease.  A true statement is that the 
cause of depression is unknown.  However, I hypothesized that the majority of ads would 
claim that depression is real illness with real causes and utilize a biochemical approach. 
By doing so, people will feel less stigmatized and more likely to seek help for depression 
if it is framed as a medical condition as opposed to a personal one.   
In general, this was supported in my analysis.  Although a few ads do not mention 
anything regarding the causes of depression, 91.79% of all advertisements seen by 
consumers contain such statements.  This is good news for the consumer.  It can be said 
that the majority of the ads are educating readers regarding the causes of depression.  
However, there are major disparities by brand; only four brands state anything about 
causes in their ads.  The three brands with the most unique ads (Effexors, Prozac, and 
Zoloft) all mentioned biochemical/medical causes in a majority of their advertisements. A 
total of 37.57% of all ads specifically state that the cause is related to a chemical 
imbalance.   There were no substantial differences in the way causes were mentioned 
depending on magazine category.  In every group of magazine, the cause mentioned with 
highest frequency was that depression could be caused by a chemical imbalance.  
However, there is one exception where my prediction does not apply.  Though every 
brand but one did not mention personal causes of depression, Prozac did so in every one 
of their unique ads.  Therefore, they simultaneously utilize the biochemical and psych-
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social theories of depression.   Therefore, 20% of all ads that are reaching the consumer 
mention personal causes.  
If the truest statement regarding causes is that it is unknown, Zoloft is the only 
brand to make it.  But since Zoloft had the greatest number of ad appearances, about a 
quarter of the ads reaching the consumer contain this statement.   Zoloft is also the only 
brand to make any statement about PMDD.  Therefore, it seems that Zoloft is the brand 
providing the most information about the causes of depression to the reader. 
 
2. Self-Diagnosis 
All brands mention the symptoms of depression but with varying frequencies.  
Every brand mentions psychological symptoms and nearly every brand mentions 
physical and depressive symptoms.  It seems that there is not one symptom or category 
of symptoms mentioned more by one brand or appearing much more frequently in any 
magazine.  The two symptoms that are mentioned most often are fatigue/low energy and 
depression sadness.  It can be inferred that the types of symptoms mentioned in the 
advertisements does not contribute to self-diagnosis.  Furthermore, neither does the 
format that the symptoms are presented in.  Though it can be argued that a checklist or 
questionnaire would facilitate self-diagnosis, this is only done by Zoloft and Effexor in 
17.20% of the total advertisements.  This is not utilized with remarkable frequency and 
therefore cannot be said to ultimately lead to self-diagnosis. 
However, there is one element of the advertisements that occurs with significant 
frequency and could contribute to self-diagnosis.  The providing of a phone number or 
website, required after 1997, is utilized by every brand in nearly every advertisement.  
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On the other hand, offering free information or a booklet is only used by Prozac and 
Zoloft in 2.12% of the ads.  Therefore, this method is rarely used and does not contribute 
substantially to consumer information about the disease effect.  One aspect I examined 
that would facilitate the doctor-patient relationship is the statement to ask, notify, or see 
one’s doctor.  This is used by every brand in every ad but one.  This is positive because 
it motivates some people to discuss depression with their doctor when they might 
otherwise not do so.  However, it is also negative if it compels patients to unnecessarily 
request a drug and cause rises in prescribing rates when it may not be needed. 
 
3. Benefits and Risks 
Some argue that antidepressant ads privilege benefits over risks and do not do an 
adequate job of presenting the fair balance between the two as required by the FDA.  
This hypothesis was not well supported by the data.  On one hand, every brand mentions 
a higher number of risks over benefits in their advertisements.  Both the benefits and 
risks differ by brand, perhaps relating to their respective pharmacology. Zoloft is the 
only brand to claim that it treats both Post Traumatic Stress Syndrome and Pre 
Menstrual Dysphonic Disorder.  Most of the risks mentioned by all brands are 
gastrointestinal or sleep related.   
On the other hand, the most frequent benefit mentioned is that there is a low 
occurrence of side effects, that they are not usually serious, and that they are well 
tolerated.  Therefore, although these ads mention a substantial number of risks, most of 
them minimize the severity of them.  Furthermore, advertisements appearing in African 
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American magazines leave out a number of risks that are mentioned in every other 
magazine category such as dizziness/lightheadedness, and weight changes.   
 
4. Type of appeal used in the advertisement 
There are two main arguments regarding the appeal of antidepressant 
advertisements.  The first is that these ads frame depression as a female condition.  
Though it is true that statistics show that females are diagnosed at a much higher rate than 
males, it is potentially dangerous to completely ignore a segment of the population where 
a certain percent suffer from this disease.  Antidepressant ads may perpetuate the over-
diagnosis of females and under-diagnosis of males.  My results provide strong evidence 
to support this hypothesis.   Of all the ads that include people (about half, Prozac is the 
only brand that never includes people), 93.41% feature a woman as the primary sufferer 
of depression.  There are only two unique advertisements by Wellbutrin that equally 
portray a woman and a man.  Furthermore, 93.41% of the time this primary person is 
Caucasian.  In only 4.19% of the ads is the person Asian and in a mere 2.39% is the 
person African-American; these ads are only for the brand Zoloft.  This means that every 
other brand in almost every ad features a white, adult, female as the typical sufferer of 
depression in need of medication.  The ads featuring African-Americans are the only ads 
that appear in African-American magazines.  Woman’s magazines feature only the 
advertisements portraying white people.  The ads featuring an Asian woman appear in 
only Young Adult and General Interest magazine.  This trend is a clear demonstration of 
target marketing on behalf of the manufacturers. 
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The other argument is that in order to adequately educate the consumer, the ads 
should be informative and include factual data as opposed to an emotional appeal that 
uses vague and qualitative terms.  I found some support for this hypothesis in my data.  
Though the brands use a variety of appeals, they are mostly motivational, anecdotal, or 
emotional.  Only Zoloft ads use factual data in the form of diagrams portraying the 
chemicals relating to depression.  However, because Zoloft has the greatest number of 
ads appearances, on the frequency level the ad appeal seen most frequently is 
informative.  This is seen in 36.77% of the advertisements.   
 
VI. CONCLUSIONS, POLICY IMPLICATIONS & RECCOMENDATIONS 
 Undoubtedly, DTC advertising both informs and persuades.  However, to what 
extent?  There are several reasons to believe that DTC advertising improves the 
prescription drug market.  It provides important medical information to the consumer and 
requires them to take the initiative in seeking medical advice.  In this sense, DTC 
advertising helps the large number of people who are potentially un-diagnosed and 
therefore, not treated.  This is especially the case for the serious medical condition of 
depression.  This all goes to the idea of consumer empowerment; letting the public know 
what is available (Calfee, 2001).  However, this is only the case when the information 
provided is not misleading or unbalanced.     
As David Healy argued in his novel The Antidepressant Era, the popularity of 
antidepressants may have been influenced more by pharmaceutical marketing rather than 
by medical necessity.  As the marketing of antidepressants have increased so have the 
cases of diagnosed depression and other related disorders.  It is possible that these 
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advertisements are in some way encouraging people to ignore the social or personal 
triggers for their depression and instead focus their attention on chemical manifestations 
and pharmacological solutions.  The problem is further exacerbated when the advertising 
targets such a small segment of the population; specifically white adult females.  Similar 
to what Grow et al found in their study, my results prove that these ads frame depression 
as a female condition.  My results are even more startling than Grow et al’s study, in that 
the advertisements in my study came not only from Reader’s Digest and Time magazines 
but magazines encompassing much larger circulation.   As Stimson argued in his article, 
this targeting practice clearly sends out the message that women are more likely than men 
to be candidates for these drugs.   
DTC advertising operates in interplay among the medical profession, the 
pharmaceutical industry, the regulatory apparatus, and the larger culture in which we live 
(Healy, 1997).  Over time, more drug companies have started using a DTC advertising 
approach.  Therefore, the issues surrounding such advertising and the possible need for 
greater government regulation are relevant not only to physicians and pharmaceutical 
companies but also to the general public.  If the role of DTC advertising is to educate, the 
relevant issue is the reliability of this source of information  As Bill Frist, Senate 
Majority Leader, stated, “We must ask ourselves: ‘Are these ads, which we know are 
costing billions, properly educating patients or just peddling expensive products?” 
(Thomaselli, 2005).  Most of the ads adequately educate consumers about the causes of 
depression, but there seems to be no consensus between brands.  Therefore, the actual 
messages received by consumers, specifically regarding causes, may be somewhat 
conflicting.  If some brands emphasize biochemical causes while others stress personal 
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causes, the consumer may become confused and hence make these efforts by the 
manufacturers pointless.   
I believe that the public must be adequately informed and educated not only on 
the causes of depression but also on the symptoms, and both benefits and risks of 
treatment.  This should be the case not only for depression but for other mental health 
disorders.  The prioritizing of benefits over risks is a serious issue raised by this study.  
Though the actual number of benefits listed did not usually outweigh the number of risks 
mentioned, it was generally indicated that these side-effects occurred infrequently.  Most 
of these ads use vague, qualitative terms to describe benefits, side-effects, and symptoms 
of depression.  The lack of data and statistics allows for interpretation by the consumer 
and can make it easier to ignore the risks and readily accept the benefits.  This can be 
potentially dangerous for the patient.  A study in the archives of General Psychiatry 
suggest that as many as 8 million Americans diagnosed as clinically depressed may just 
be reacting normally to stressful events like losing a job, the loss of a loved one, or a 
divorce. 
Undoubtedly, the main goal of advertising has always been to increase sales.  
Consumers must be aware of pharmaceutical manufacturer’s tactics and be well informed 
in order to make the smartest decisions for their health and well-being.  In addition, the 
FDA must analyze their regulatory approach so that the flow of information through 
advertising is as educational and useful as possible.  Any standards regarding more 
complete information would be beneficial to physicians and to the public.  The most 
realistic recommendation is that the FDA should require approval of these ads before 
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they reach the public.  Simply requiring that an advertisement “cannot be false or 
misleading” and “must present information that is not inconsistent with the product label” 
is not enough; misleading content undoubtedly reaches the consumer.  It is necessary for 
the FDA to compare antidepressant advertisements to scientific evidence to ensure that 
the messages received by potential patients are 100% accurate.  The issue for policy 
makers is not whether DTC advertising should be banned, but instead how to maximize 
the benefits and minimize the risks.  Currently there are two policy initiatives that seem 
promising.  One includes a two-year moratorium on DTC advertising of new drugs 
combined with a requirement for systematic postmarketing surveillance.  The other is to 
use the tax system to create incentives for public-private consortia to produce mass media 
campaigns aimed at educating patients about common but serious medical conditions. 
Either way, the main goal of any policy initiative should be to harness of the power of 
DTC advertising to improve public health.   
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Appendix 1: Code of Federal Regulations - Title 21 Food and Drugs  
PART 202—PRESCRIPTION DRUG ADVERTISING 
Authority: 
21 U.S.C. 321, 331, 352, 355, 360b, 371. 
§202.1 Prescription-drug advertisements. 
(a)(1) The ingredient information required by section 502(n) of the Federal Food, Drug, 
and Cosmetic Act shall appear together, without any intervening written, printed, or 
graphic matter, except the proprietary names of ingredients, which may be included with 
the listing of established names. 
(2) The order of listing of ingredients in the advertisement shall be the same as the order 
of listing of ingredients on the label of the product, and the information presented in the 
advertisement concerning the quantity of each such ingredient shall be the same as the 
corresponding information on the label of the product. 
(3) The advertisement shall not employ a fanciful proprietary name for the drug or any 
ingredient in such a manner as to imply that the drug or ingredient has some unique 
effectiveness or composition, when, in fact, the drug or ingredient is a common 
substance, the limitations of which are readily recognized when the drug or ingredient is 
listed by its established name. 
(4) The advertisement shall not feature inert or inactive ingredients in a manner that 
creates an impression of value greater than their true functional role in the formulation. 
(5) The advertisement shall not designate a drug or ingredient by a proprietary name that, 
because of similarity in spelling or pronunciation, may be confused with the proprietary 
name or the established name of a different drug or ingredient. 
(b)(1) If an advertisement for a prescription drug bears a proprietary name or designation 
for the drug or any ingredient thereof, the established name, if such there be, 
corresponding to such proprietary name or designation shall accompany such proprietary 
name or designation each time it is featured in the advertisement for the drug; but, except 
as provided below in this subparagraph, the established name need not be used with the 
proprietary name or designation in the running text of the advertisement. On any page of 
an advertisement in which the proprietary name or designation is not featured but is used 
in the running text, the established name shall be used at least once in the running text in 
association with such proprietary name or designation and in the same type size used in 
the running text: Provided, however, That if the proprietary name or designation is used 
in the running text in larger size type, the established name shall be used at least once in 
association with, and in type at least half as large as the type used for, the most prominent 
presentation of the proprietary name or designation in such running text. If any 
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advertisement includes a column with running text containing detailed information as to 
composition, prescribing, side effects, or contraindications and the proprietary name or 
designation is used in such column but is not featured above or below the column, the 
established name shall be used at least once in such column of running text in association 
with such proprietary name or designation and in the same type size used in such column 
of running text: Provided, however, That if the proprietary name or designation is used in 
such column of running text in larger size type, the established name shall be used at least 
once in association with, and in type at least half as large as the type used for, the most 
prominent presentation of the proprietary name or designation in such column of running 
text. Where the established name is required to accompany or to be used in association 
with the proprietary name or designation, the established name shall be placed in direct 
conjunction with the proprietary name or designation, and the relationship between the 
proprietary name or designation and the established name shall be made clear by use of a 
phrase such as “brand of” preceding the established name, by brackets surrounding the 
established name, or by other suitable means. 
(2) The established name shall be printed in letters that are at least half as large as the 
letters comprising the proprietary name or designation with which it is joined, and the 
established name shall have a prominence commensurate with the prominence with 
which such proprietary name or designation appears, taking into account all pertinent 
factors, including typography, layout, contrast, and other printing features. 
(c) In the case of a prescription drug containing two or more active ingredients, if the 
advertisement bears a proprietary name or designation for such mixture and there is no 
established name corresponding to such proprietary name or designation, the quantitative 
ingredient information required in the advertisement by section 502(n) of the act shall be 
placed in direct conjunction with the most prominent display of the proprietary name or 
designation. The prominence of the quantitative ingredient information shall bear a 
reasonable relationship to the prominence of the proprietary name. 
(d)(1) If the advertisement employs one proprietary name or designation to refer to a 
combination of active ingredients present in more than one preparation (the individual 
preparations differing from each other as to quantities of active ingredients and/or the 
form of the finished preparation) and there is no established name corresponding to such 
proprietary name or designation, a listing showing the established names of the active 
ingredients shall be placed in direct conjunction with the most prominent display of such 
proprietary name or designation. The prominence of this listing of active ingredients shall 
bear a reasonable relationship to the prominence of the proprietary name and the 
relationship between such proprietary name or designation, and the listing of active 
ingredients shall be made clear by use of such phrase as “brand of”, preceding the listing 
of active ingredients. 
(2) The advertisement shall prominently display the name of at least one specific dosage 
form and shall have the quantitative ingredient information required by section 502(n) of 
the act in direct conjunction with such display. If other dosage forms are listed in the 
advertisement, the quantitative ingredient information for such dosage forms shall appear 
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in direct conjunction and in equal prominence with the most prominent listing of the 
names of such dosage forms. 
(e) True statement of information in brief summary relating to side effects, 
contraindications, and effectiveness: 
(1) When required. All advertisements for any prescription drug (“prescription drug” as 
used in this section means drugs defined in section 503(b)(1) of the act and §201.105, 
applicable to drugs for use by man and veterinary drugs, respectively), except 
advertisements described in paragraph (e)(2) of this section, shall present a true statement 
of information in brief summary relating to side effects, contraindications (when used in 
this section “side effects, contraindications” include side effects, warnings, precautions, 
and contraindications and include any such information under such headings as cautions, 
special considerations, important notes, etc.) and effectiveness. Advertisements broadcast 
through media such as radio, television, or telephone communications systems shall 
include information relating to the major side effects and contraindications of the 
advertised drugs in the audio or audio and visual parts of the presentation and unless 
adequate provision is made for dissemination of the approved or permitted package 
labeling in connection with the broadcast presentation shall contain a brief summary of 
all necessary information related to side effects and contraindications. 
(2) Exempt advertisements. The following advertisements are exempt from the 
requirements of paragraph (e)(1) of this section under the conditions specified: 
(i) Reminder advertisements. Reminder advertisements are those which call attention to 
the name of the drug product but do not include indications or dosage recommendations 
for use of the drug product. These reminder advertisements shall contain only the 
proprietary name of the drug product, if any; the established name of the drug product, if 
any; the established name of each active ingredient in the drug product; and, optionally, 
information relating to quantitative ingredient statements, dosage form, quantity of 
package contents, price, the name and address of the manufacturer, packer, or distributor 
or other written, printed, or graphic matter containing no representation or suggestion 
relating to the advertised drug product. If the Commissioner finds that there is evidence 
of significant incidence of fatalities or serious injury associated with the use of a 
particular prescription drug, he may withdraw this exemption by so notifying the 
manufacturer, packer, or distributor of the drug by letter. Reminder advertisements, other 
than those solely intended to convey price information including, but not limited to, those 
subject to the requirements of §200.200 of this chapter, are not permitted for a 
prescription drug product whose labeling contains a boxed warning relating to a serious 
hazard associated with the use of the drug product. Reminder advertisements which are 
intended to provide consumers with information concerning the price charged for a 
prescription for a drug product are exempt from the requirements of this section if they 
meet all of the conditions contained in §200.200 of this chapter. Reminder 
advertisements, other than those subject to the requirements of §200.200 of this chapter, 
are not permitted for a drug for which an announcement has been published pursuant to a 
review on the labeling claims for the drug by the National Academy of Sciences/National 
 128 
 
Research Council (NAS/NRC), Drug Efficacy Study Group, and for which no claim has 
been evaluated as higher than “possibly effective.” If the Commissioner finds the 
circumstances are such that a reminder advertisement may be misleading to prescribers of 
drugs subject to NAS/NRC evaluation, such advertisements will not be allowed and the 
manufacturer, packer, or distributor will be notified either in the publication of the 
conclusions on the effectiveness of the drug or by letter. 
(ii) Advertisements of bulk-sale drugs. Advertisements of bulk-sale drugs that promote 
sale of the drug in bulk packages in accordance with the practice of the trade solely to be 
processed, manufactured, labeled, or repackaged in substantial quantities and that contain 
no claims for the therapeutic safety or effectiveness of the drug. 
(iii) Advertisements of prescription-compounding drugs. Advertisements of prescription-
compounding drugs that promote sale of a drug for use as a prescription chemical or 
other compound for use by registered pharmacists in compounding prescriptions if the 
drug otherwise complies with the conditions for the labeling exemption contained in 
§201.120 and the advertisement contains no claims for the therapeutic safety or 
effectiveness of the drug. 
(3) Scope of information to be included; applicability to the entire advertisement. (i) The 
requirement of a true statement of information relating to side effects, contraindications, 
and effectiveness applies to the entire advertisement. Untrue or misleading information in 
any part of the advertisement will not be corrected by the inclusion in another distinct 
part of the advertisement of a brief statement containing true information relating to side 
effects, contraindications, and effectiveness of the drug. If any part or theme of the 
advertisement would make the advertisement false or misleading by reason of the 
omission of appropriate qualification or pertinent information, that part or theme shall 
include the appropriate qualification or pertinent information, which may be concise if it 
is supplemented by a prominent reference on each page to the presence and location 
elsewhere in the advertisement of a more complete discussion of such qualification or 
information. 
(ii) The information relating to effectiveness is not required to include information 
relating to all purposes for which the drug is intended but may optionally be limited to a 
true statement of the effectiveness of the drug for the selected purpose(s) for which the 
drug is recommended or suggested in the advertisement. The information relating to 
effectiveness shall include specific indications for use of the drug for purposes claimed in 
the advertisement; for example, when an advertisement contains a broad claim that a drug 
is an antibacterial agent, the advertisement shall name a type or types of infections and 
microorganisms for which the drug is effective clinically as specifically as required, 
approved, or permitted in the drug package labeling. 
(iii) The information relating to side effects and contraindications shall disclose each 
specific side effect and contraindication (which include side effects, warnings, 
precautions, and contraindications and include any such information under such headings 
as cautions, special considerations, important notes, etc.; see paragraph (e)(1) of this 
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section) contained in required, approved, or permitted labeling for the advertised drug 
dosage form(s): Provided, however, 
(a) The side effects and contraindications disclosed may be limited to those pertinent to 
the indications for which the drug is recommended or suggested in the advertisement to 
the extent that such limited disclosure has previously been approved or permitted in drug 
labeling conforming to the provisions of §§201.100 or 201.105; and 
(b) The use of a single term for a group of side effects and contraindications (for 
example, “blood dyscrasias” for disclosure of “leukopenia,” “agranulocytosis,” and 
“neutropenia”) is permitted only to the extent that the use of such a single term in place 
of disclosure of each specific side effect and contraindication has been previously 
approved or permitted in drug labeling conforming to the provisions of §§201.100 or 
201.105. 
(4) Substance of information to be included in brief summary. (i)(a) An advertisement for 
a prescription drug covered by a new-drug application approved pursuant to section 505 
of the act after October 10, 1962 or section 512 of the act after August 1, 1969, or any 
approved supplement thereto, shall not recommend or suggest any use that is not in the 
labeling accepted in such approved new-drug application or supplement. The 
advertisement shall present information from labeling required, approved, or permitted in 
a new-drug application relating to each specific side effect and contraindication in such 
labeling that relates to the uses of the advertised drug dosage form(s) or shall otherwise 
conform to the provisions of paragraph (e)(3)(iii) of this section. 
(b) If a prescription drug was covered by a new-drug application or a supplement thereto 
that became effective prior to October 10, 1962, an advertisement may recommend or 
suggest: 
(1) Uses contained in the labeling accepted in such new-drug application and any 
effective, approved, or permitted supplement thereto. 
(2) Additional uses contained in labeling in commercial use on October 9, 1962, to the 
extent that such uses did not cause the drug to be an unapproved “new drug” as “new 
drug” was defined in section 201(p) of the act as then in force, and to the extent that such 
uses would be permitted were the drug subject to paragraph (e)(4)(iii) of this section. 
(3) Additional uses contained in labeling in current commercial use to the extent that such 
uses do not cause the drug to be an unapproved “new drug” as defined in section 201(p) 
of the act as amended or a “new animal drug” as defined in section 201(v) of the act as 
amended. 
The advertisement shall present information from labeling required, approved, or 
permitted in a new-drug application relating to each specific side effect and 
contraindication in such labeling that relates to the uses of the advertised drug dosage 
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form(s) or shall otherwise conform to the provisions of paragraph (e)(3)(iii) of this 
section. 
(ii) In the case of an advertisement for a prescription drug other than a drug the labeling 
of which causes it to be an unapproved “new drug” and other than drugs covered by 
paragraph (e)(4)(i) of this section, an advertisement may recommend and suggest the 
drug only for those uses contained in the labeling thereof: 
(a) For which the drug is generally recognized as safe and effective among experts 
qualified by scientific training and experience to evaluate the safety and effectiveness of 
such drugs; or 
(b) For which there exists substantial evidence of safety and effectiveness, consisting of 
adequate and well-controlled investigations, including clinical investigations (as used in 
this section “clinical investigations,” “clinical experience,” and “clinical significance” 
mean in the case of drugs intended for administration to man, investigations, experience, 
or significance in humans, and in the case of drugs intended for administration to other 
animals, investigations, experience, or significance in the specie or species for which the 
drug is advertised), by experts qualified by scientific training and experience to evaluate 
the safety and effectiveness of the drug involved, on the basis of which it can fairly and 
responsibly be concluded by such experts that the drug is safe and effective for such uses; 
or 
(c) For which there exists substantial clinical experience (as used in this section this 
means substantial clinical experience adequately documented in medical literature or by 
other data (to be supplied to the Food and Drug Administration, if requested)), on the 
basis of which it can fairly and responsibly be concluded by qualified experts that the 
drug is safe and effective for such uses; or 
(d) For which safety is supported under any of the preceding clauses in paragraphs 
(e)(4)(iii) (a), (b), and (c) of this section and effectiveness is supported under any other of 
such clauses. 
The advertisement shall present information relating to each specific side effect and 
contraindication that is required, approved, or permitted in the package labeling by 
§§201.100 or 201.105 of this chapter of the drug dosage form(s) or shall otherwise 
conform to the provisions of paragraph (e)(3)(iii) of this section. 
(5) “True statement” of information. An advertisement does not satisfy the requirement 
that it present a “true statement” of information in brief summary relating to side effects, 
contraindications, and effectiveness if: 
(i) It is false or misleading with respect to side effects, contraindications, or effectiveness; 
or 
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(ii) It fails to present a fair balance between information relating to side effects and 
contraindications and information relating to effectiveness of the drug in that the 
information relating to effectiveness is presented in greater scope, depth, or detail than is 
required by section 502(n) of the act and this information is not fairly balanced by a 
presentation of a summary of true information relating to side effects and 
contraindications of the drug; Provided, however, That no advertisement shall be 
considered to be in violation of this section if the presentation of true information relating 
to side effects and contraindications is comparable in depth and detail with the claims for 
effectiveness or safety. 
(iii) It fails to reveal facts material in the light of its representations or material with 
respect to consequences that may result from the use of the drug as recommended or 
suggested in the advertisement. 
(6) Advertisements that are false, lacking in fair balance, or otherwise misleading. An 
advertisement for a prescription drug is false, lacking in fair balance, or otherwise 
misleading, or otherwise violative of section 502(n) of the act, among other reasons, if it: 
(i) Contains a representation or suggestion, not approved or permitted for use in the 
labeling, that a drug is better, more effective, useful in a broader range of conditions or 
patients (as used in this section patients means humans and in the case of veterinary 
drugs, other animals), safer, has fewer, or less incidence of, or less serious side effects or 
contraindications than has been demonstrated by substantial evidence or substantial 
clinical experience (as described in paragraphs (e)(4)(ii) (b) and (c) of this section) 
whether or not such representations are made by comparison with other drugs or 
treatments, and whether or not such a representation or suggestion is made directly or 
through use of published or unpublished literature, quotations, or other references. 
(ii) Contains a drug comparison that represents or suggests that a drug is safer or more 
effective than another drug in some particular when it has not been demonstrated to be 
safer or more effective in such particular by substantial evidence or substantial clinical 
experience. 
(iii) Contains favorable information or opinions about a drug previously regarded as valid 
but which have been rendered invalid by contrary and more credible recent information, 
or contains literature references or quotations that are significantly more favorable to the 
drug than has been demonstrated by substantial evidence or substantial clinical 
experience. 
(iv) Contains a representation or suggestion that a drug is safer than it has been 
demonstrated to be by substantial evidence or substantial clinical experience, by selective 
presentation of information from published articles or other references that report no side 
effects or minimal side effects with the drug or otherwise selects information from any 
source in a way that makes a drug appear to be safer than has been demonstrated. 
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(v) Presents information from a study in a way that implies that the study represents 
larger or more general experience with the drug than it actually does. 
(vi) Contains references to literature or studies that misrepresent the effectiveness of a 
drug by failure to disclose that claimed results may be due to concomitant therapy, or by 
failure to disclose the credible information available concerning the extent to which 
claimed results may be due to placebo effect (information concerning placebo effect is 
not required unless the advertisement promotes the drug for use by man). 
(vii) Contains favorable data or conclusions from nonclinical studies of a drug, such as in 
laboratory animals or in vitro, in a way that suggests they have clinical significance when 
in fact no such clinical significance has been demonstrated. 
(viii) Uses a statement by a recognized authority that is apparently favorable about a drug 
but fails to refer to concurrent or more recent unfavorable data or statements from the 
same authority on the same subject or subjects. 
(ix) Uses a quote or paraphrase out of context to convey a false or misleading idea. 
(x) Uses literature, quotations, or references that purport to support an advertising claim 
but in fact do not support the claim or have relevance to the claim. 
(xi) Uses literature, quotations, or references for the purpose of recommending or 
suggesting conditions of drug use that are not approved or permitted in the drug package 
labeling. 
(xii) Offers a combination of drugs for the treatment of patients suffering from a 
condition amenable to treatment by any of the components rather than limiting the 
indications for use to patients for whom concomitant therapy as provided by the fixed 
combination drug is indicated, unless such condition is included in the uses permitted 
under paragraph (e)(4) of this section. 
(xiii) Uses a study on normal individuals without disclosing that the subjects were 
normal, unless the drug is intended for use on normal individuals. 
(xiv) Uses “statistics” on numbers of patients, or counts of favorable results or side 
effects, derived from pooling data from various insignificant or dissimilar studies in a 
way that suggests either that such “statistics” are valid if they are not or that they are 
derived from large or significant studies supporting favorable conclusions when such is 
not the case. 
(xv) Uses erroneously a statistical finding of “no significant difference” to claim clinical 
equivalence or to deny or conceal the potential existence of a real clinical difference. 
(xvi) Uses statements or representations that a drug differs from or does not contain a 
named drug or category of drugs, or that it has a greater potency per unit of weight, in a 
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way that suggests falsely or misleadingly or without substantial evidence or substantial 
clinical experience that the advertised drug is safer or more effective than such other drug 
or drugs. 
(xvii) Uses data favorable to a drug derived from patients treated with dosages different 
from those recommended in approved or permitted labeling if the drug advertised is 
subject to section 505 of the act, or, in the case of other drugs, if the dosages employed 
were different from those recommended in the labeling and generally recognized as safe 
and effective. This provision is not intended to prevent citation of reports of studies that 
include some patients treated with dosages different from those authorized, if the results 
in such patients are not used. 
(xviii) Uses headline, subheadline, or pictorial or other graphic matter in a way that is 
misleading. 
(xix) Represents or suggests that drug dosages properly recommended for use in the 
treatment of certain classes of patients or disease conditions are safe and effective for the 
treatment of other classes of patients or disease conditions when such is not the case. 
(xx) Presents required information relating to side effects or contraindications by means 
of a general term for a group in place of disclosing each specific side effect and 
contraindication (for example employs the term blood dyscrasias instead of 
“leukopenia,” “agranulocytosis,” “neutropenia,” etc.) unless the use of such general term 
conforms to the provisions of paragraph (e)(3)(iii) of this section. 
Provided, however, That any provision of this paragraph shall be waived with respect to a 
specified advertisement as set forth in a written communication from the Food and Drug 
Administration on a petition for such a waiver from a person who would be adversely 
affected by the enforcement of such provision on the basis of a showing that the 
advertisement is not false, lacking in fair balance, or otherwise misleading, or otherwise 
violative of section 502(n) of the act. A petition for such a waiver shall set forth clearly 
and concisely the petitioner's interest in the advertisement, the specific provision of this 
paragraph from which a waiver is sought, a complete copy of the advertisement, and a 
showing that the advertisement is not false, lacking in fair balance, or otherwise 
misleading, or otherwise violative of section 502(n) of the act. 
(7) Advertisements that may be false, lacking in fair balance, or otherwise misleading. 
An advertisement may be false, lacking in fair balance, or otherwise misleading or 
otherwise violative of section 502(n) of the act if it: 
(i) Contains favorable information or conclusions from a study that is inadequate in 
design, scope, or conduct to furnish significant support for such information or 
conclusions. 
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(ii) Uses the concept of “statistical significance” to support a claim that has not been 
demonstrated to have clinical significance or validity, or fails to reveal the range of 
variations around the quoted average results. 
(iii) Uses statistical analyses and techniques on a retrospective basis to discover and cite 
findings not soundly supported by the study, or to suggest scientific validity and rigor for 
data from studies the design or protocol of which are not amenable to formal statistical 
evaluations. 
(iv) Uses tables or graphs to distort or misrepresent the relationships, trends, differences, 
or changes among the variables or products studied; for example, by failing to label 
abscissa and ordinate so that the graph creates a misleading impression. 
(v) Uses reports or statements represented to be statistical analyses, interpretations, or 
evaluations that are inconsistent with or violate the established principles of statistical 
theory, methodology, applied practice, and inference, or that are derived from clinical 
studies the design, data, or conduct of which substantially invalidate the application of 
statistical analyses, interpretations, or evaluations. 
(vi) Contains claims concerning the mechanism or site of drug action that are not 
generally regarded as established by scientific evidence by experts qualified by scientific 
training and experience without disclosing that the claims are not established and the 
limitations of the supporting evidence. 
(vii) Fails to provide sufficient emphasis for the information relating to side effects and 
contraindications, when such information is contained in a distinct part of an 
advertisement, because of repetition or other emphasis in that part of the advertisement of 
claims for effectiveness or safety of the drug. 
(viii) Fails to present information relating to side effects and contraindications with a 
prominence and readability reasonably comparable with the presentation of information 
relating to effectiveness of the drug, taking into account all implementing factors such as 
typography, layout, contrast, headlines, paragraphing, white space, and any other 
techniques apt to achieve emphasis. 
(ix) Fails to provide adequate emphasis (for example, by the use of color scheme, 
borders, headlines, or copy that extends across the gutter) for the fact that two facing 
pages are part of the same advertisement when one page contains information relating to 
side effects and contraindications. 
(x) In an advertisement promoting use of the drug in a selected class of patients (for 
example, geriatric patients or depressed patients), fails to present with adequate emphasis 
the significant side effects and contraindications or the significant dosage considerations, 
when dosage recommendations are included in an advertisement, especially applicable to 
that selected class of patients. 
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(xi) Fails to present on a page facing another page (or on another full page) of an 
advertisement on more than one page, information relating to side effects and 
contraindications when such information is in a distinct part of the advertisement. 
(xii) Fails to include on each page or spread of an advertisement the information relating 
to side effects and contraindications or a prominent reference to its presence and location 
when it is presented as a distinct part of an advertisement. 
(xiii) Contains information from published or unpublished reports or opinions falsely or 
misleadingly represented or suggested to be authentic or authoritative. 
(f)–(i) [Reserved] 
(j)(1) No advertisement concerning a particular prescription drug may be disseminated 
without prior approval by the Food and Drug Administration if: 
(i) The sponsor or the Food and Drug Administration has received information that has 
not been widely publicized in medical literature that the use of the drug may cause 
fatalities or serious damage; 
(ii) The Commissioner (or in his absence the officer acting as Commissioner), after 
evaluating the reliability of such information, has notified the sponsor that the 
information must be a part of the advertisements for the drug; and 
(iii) The sponsor has failed within a reasonable time as specified in such notification to 
present to the Food and Drug Administration a program, adequate in light of the nature of 
the information, for assuring that such information will be publicized promptly and 
adequately to the medical profession in subsequent advertisements. 
If the Commissioner finds that the program presented is not being followed, he will 
notify the sponsor that prior approval of all advertisements for the particular drug will be 
required. Nothing in this paragraph is to be construed as limiting the Commissioner's or 
the Secretary's rights, as authorized by law, to issue publicity, to suspend any new-drug 
application, to decertify any antibiotic, or to recommend any regulatory action. 
(2) Within a reasonable time after information concerning the possibility that a drug may 
cause fatalities or serious damage has been widely publicized in medical literature, the 
Food and Drug Administration shall notify the sponsor of the drug by mail that prior 
approval of advertisements for the drug is no longer necessary. 
(3) Dissemination of an advertisement not in compliance with this paragraph shall be 
deemed to be an act that causes the drug to be misbranded under section 502(n) of the act. 
(4) Any advertisement may be submitted to the Food and Drug Administration prior to 
publication for comment. If the advertiser is notified that the submitted advertisement is 
not in violation and, at some subsequent time, the Food and Drug Administration changes 
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its opinion, the advertiser will be so notified and will be given a reasonable time for 
correction before any regulatory action is taken under this section. Notification to the 
advertiser that a proposed advertisement is or is not considered to be in violation shall be 
in written form. 
(5) The sponsor shall have an opportunity for a regulatory hearing before the Food and 
Drug Administration pursuant to part 16 of this chapter with respect to any determination 
that prior approval is required for advertisements concerning a particular prescription 
drug, or that a particular advertisement is not approvable. 
(k) An advertisement issued or caused to be issued by the manufacturer, packer, or 
distributor of the drug promoted by the advertisement and which is not in compliance 
with section 502(n) of the act and the applicable regulations thereunder shall cause stocks 
of such drug in possession of the person responsible for issuing or causing the issuance of 
the advertisement, and stocks of the drug distributed by such person and still in the 
channels of commerce, to be misbranded under section 502(n) of the act. 
(l)(1) Advertisements subject to section 502(n) of the act include advertisements in 
published journals, magazines, other periodicals, and newspapers, and advertisements 
broadcast through media such as radio, television, and telephone communication systems. 
(2) Brochures, booklets, mailing pieces, detailing pieces, file cards, bulletins, calendars, 
price lists, catalogs, house organs, letters, motion picture films, film strips, lantern slides, 
sound recordings, exhibits, literature, and reprints and similar pieces of printed, audio, or 
visual matter descriptive of a drug and references published (for example, the “Physicians 
Desk Reference”) for use by medical practitioners, pharmacists, or nurses, containing 
drug information supplied by the manufacturer, packer, or distributor of the drug and 
which are disseminated by or on behalf of its manufacturer, packer, or distributor are 
hereby determined to be labeling as defined in section 201(m) of the act. 
[40 FR 14016, Mar. 27, 1975, as amended at 40 FR 58799, Dec. 18, 1975; 41 FR 48266, 
Nov. 2, 1976; 42 FR 15674, Mar. 22, 1977; 60 FR 38480, July 27, 1995; 64 FR 400, Jan. 
5, 1999] 
Effective Date Note: 
At 44 FR 37467, June 26, 1979, §202.1(e)(6) (ii) and (vii) were revised. At 44 FR 74817, 
Dec. 18, 1979, paragraphs (e)(6) (ii) and (vii) were stayed indefinitely. At 64 FR 400, 
Jan. 5, 1999, these paragraphs were amended. For the convenience of the user, 
paragraphs (e)(6) (ii) and (vii), published at 44 FR 37467, are set forth below: 
§202.1 Prescription–drug advertisements. 
 (ii) Represents or suggests that a prescription drug is safer or more effective than another 
drug in some particular when the difference has not been demonstrated by substantial 
evidence. An advertisement for a prescription drug may not, either directly or by 
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implication, e.g., by use of comparative test data or reference to published reports, 
represent that the drug is safer or more effective than another drug, nor may an 
advertisement contain a quantitative statement of safety or effectiveness (a) unless the 
representation has been approved as part of the labeling in a new drug application or 
biologic license, or (b) if the drug is not a new drug or biologic, unless the representation 
of safety or effectiveness is supported by substantial evidence derived from adequate and 
well–controlled studies as defined in §314.111(a)(5)(ii) of this chapter, or unless the 
requirement for adequate and well–controlled studies is waived as provided in 
§314.111(a)(5)(ii) of this chapter. 
(vii) Suggests, on the basis of favorable data or conclusions from nonclinical studies of a 
prescription drug, such as studies in laboratory animals or in vitro, that the studies have 
clinical significance, if clinical significance has not been demonstrated. Data that 
demonstrate activity or effectiveness for a prescription drug in animal or in vitro tests and 
have not been shown by adequate and well–controlled clinical studies to pertain to 
clinical use may be used in advertising except that (a), in the case of anti–infective drugs, 
in vitro data may be included in the advertisement, if data are immediately preceded by 
the statement “The following in vitro data are available but their clinical significance is 
unknown” and (b), in the case of other drug classes, in vitro and animal data that have not 
been shown to pertain to clinical use by adequate and well–controlled clinical studies as 
defined in §314.111(a)(5)(ii) of this chapter may not be used unless the requirement for 
adequate and well–controlled studies is waived as provided in §314.111(a)(5)(ii) of this 
chapter. 
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Appendix 2 
Pharmaceutical Industry Issues DTC Ad Guidelines: 
Softball Approach Rejects Calls for Restrictions or Moratorium 
Text of PhRMA Principles 
PhRMA Guiding Principles on Direct to Consumer Advertisements About Prescription 
Medicines  
 
To express the commitment of PhRMA members to deliver DTC communicataions that 
serve as valuable contributors to public health, PhRMA has established the following 
voluntary guiding principles. 
 
1.  These principles are premised on the recognition that DTC advertising of prescription 
medicines can benefit the public health by increasing awareness about diseases, educating 
patients about treatment options, motivating patients to contact their physicians and 
engage in a dialogue about health concerns, increasing the likelihood that patients will 
receive appropriate care for conditions that are frequently under-diagnosed and under-
treated, and encouraging compliance with prescription drug treatment regimens. 
 
2. In accordance with FDA regulations, all DTC information should be accurate and not 
misleading, should make claims only when supported by substantial evidence, should 
reflect balance between risks and benefits, and should be consistent with FDA approved 
labeling. 
 
3. DTC television and print advertising which is designed to market a prescription drug 
should also be designed to responsibly educate the consumer about that medicine and, 
where appropriate, the condition for which it may be prescribed. 
 
4.  DTC television and print advertising of prescription drugs should clearly indicate that 
the medicine is a prescription drug to distinguish such advertising from other advertising 
for non-prescription products. 
 
5.  DTC television and print advertising should foster responsible communications 
between patients and health care professionals to help patients achieve better health and a 
more complete appreciation of both the health benefits and the known risks associated 
with the medicine being advertised.   
 
6.  In order to foster responsible communication between patients and health care 
professionals, companies should spend an appropriate amount of time to educate health 
professionals about a new medicine or a new therapeutic indication before commencing 
the first DTC advertising campaign.  In determining what constitutes an appropriate time, 
companies should take into account the relative importance of informing patients of the 
availability of a new medicine, the complexity of the risk-benefit profile of that new 
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medicine and health care professionals’ knowledge of the condition being treated.  
Companies should continue to educate health care professionals as additional valid 
information about a new medicine is obtained from all reliable sources. 
 
7.  Working with the FDA, companies should continue to responsibly alter or discontinue 
a DTC advertising campaign should new and reliable information indicated a serious 
previously unknown safety risk. 
 
8.  Companies should submit all new DTC television advertisements to the FDA before 
releasing these advertisements for broadcast.  
 
9.  DTC television and print advertising should include information about the availability 
of other options such as diet and lifestyle changes where appropriate for the advertised 
condition. 
 
10.  DTC television advertising that identifies a product by name should clearly state the 
health conditions for which the medicine is approved and the major risks associated with 
the medicine being advertised. 
 
11.  DTC television and print advertising should be designed to achieve a balance 
presentation of both the benefits and the risks associated with the advertised prescription 
medicine.   
 
12.  All DTC advertising should respect the seriousness of the health conditions and the 
medicine being advertised. 
 
13.  In terms of content and placement, DTC television and print advertisements should 
be targeted to avoid audiences that are not age appropriate for the messages involved. 
 
14.  Companies are encouraged to promote health and disease awareness as part of their 
DTC advertising. 
 
15.  Companies are encouraged to include information in all DTC advertising, where 
feasible, about help for the uninsured and underinsured.   
 
 
** source: Thomaselli, R.  (2005, August 2).  Pharmaceutical industry issues DTC ad 
guidelines: Softball approach rejects calls for restrictions or moratorium.  
www.adage.com/paypoints/buyArticle.cms/ 
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Appendix 3 
1995 1996 1997 1998 1999 2000  2001 2002 2003 2004 2005  
N % N % N % N % N % N % N % N % N % N % N % 
CELEXA 0 0 0 0 0 0 0 0 0 0 0 0 1 3.33 0 0 0 0 0 0 0 0 
SERZONE 0 0 0 0 1 2.56 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
EFFEXOR  & 
EFFEXOR XR 
6 60 8 66.67 0 0 0 0 0 0 0 0 0 0 0 0 26 21.49 6 8.96 0 0 
PAXIL CR 0 0 0 0 0 0 0 0 0 0 0 0 0 0 12 66.67 9 7.44 6 8.96 0 0 
PROZAC 0 0 0 0 38 97.44 49 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
WELLBUTRIN 
SR & XL 
0 0 1 8.33 0 0 0 0 0 0 0 0 4 13.33 0 0 10 8.26 23 34.33 9 28.13 
ZOLOFT 0 0 0 0 0 0 0 0 0 0 0 0 25 83.33 6 33.33 76 62.81 32 47.76 23 71.88 
TOTAL 10 100 12 100 39 100 49 100 0 100 0 100 30 100 18 100 121 100 67 100 32 100 
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Appendix 4 
CODING FORM FOR PSYCHIATRIC MEDICINE/ANTIDEPRESSANTS 
 
UNIQUE AD NUMBER_________________ 
BRAND NUMBER _____________________ 
 
Type of ad                           □ Advertisement         □ Other____________ 
(check all that apply)           □ Preview Ad 
Sponsors________________________________      
                  
     Ad Length 
     □1pg                                    □<.25pg 
     □2pgs          and…              □.25 pg 
     □3pgs                                  □.5pg 
     □4pgs                                  □.75pg 
     □>4pgs 
     Directive Length 
     □1pg                                    □.25pg 
     □2pgs          and…              □.5 pg 
     □3pgs                                  □.75pg 
      
      Product  
____________________________                                                                                               
     Product Type       □ Tablet     □ Capsule     □ Not Specified     □ Other____________ 
 
□ Dosage not specified   
      Dosage                 ______mg  □ n/a                    ______mg  □ n/a                     
      Frequency         □D □W □M □O_____          □D □W □M □O_____         
                                         □ not specified                         □ not specified                   
 
                                ______mg  □ n/a                    ______mg  □ n/a          
                             □D □W □M □O_____            □D □W □M □O_____    
                                □ not specified                           □ not specified 
      Manufacturer     
____________________________      
Number _______                                □  Unable to be determined   
     Design of Ad        □ Color          □ Black & White        □ Microfiche 
     Ad Visual  (check all that apply)          
                            □ Picture        □ Product         □ Text       □  chart/quiz/questionnaire 
      Tagline      
____________________________________ 
Number _____                                                               □ No tagline in ad 
     Administration            □ By prescription only          □ Not identified in ad          
     Directives (check all that apply)        □  None 
    □ Caution if used w/ tricyclic antidepressant (TCA)                                                                 
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    □ Tell your doctor about other medications/ other conditions you have.                        
    □ Have blood pressure monitored regularly      □ Ask/Notify/See your doctor     
         □ Ask your sales representative 
    □ Read important information on next page      □ Not approved for pediatric patients 
    □ Patients should be observed closely for changes in behavior/worsening condition      
         
                                    Do Not Use if… 
 □ using MAO inhibitors  □ using Seldane, Hismanal, Halcion or Propulsid                              
□ using Bupropion/pimozide/thioridazine           □ pregnant/nursing   
□ have had seizure or eating disorder   
 □ Glaucoma  □ Renal disease/impairment  □ alcohol use   
□ hepatic insufficient 
□ Allergies to product  □ hypersensitive to escitalopram oxalate 
□ Under 18  □ stop using alcohol/sedatives 
                           □ Other______________________________________ 
 
   Side Effects (check all that apply)            □  None Specified 
     □ Dry mouth       □ Diarrhea, constipation, upset stomach    □ Nausea                                   
     □ Drowsiness/sleepiness/yawn   □ Insomnia     □ Sexual impairment               
      □ Dizziness/lightheadedness  □ Lack of energy/weakness   □ Muscle pain 
      □ Anxiety/nervousness/agitation    □ Sweating   □ Headaches     □ Seizure/tremor       
      □ Weight changes/anorexia     □ Increased blood pressure     □ Rash  □ Injury/trauma       
     □ Decreased appetite   □ Vision impairment  □ Sore throat  □ Suicidal Thoughts/actions 
    □ Infection   
                     □ Other______________________________________                                          
                                              
    
 Product Claims (check all that apply)            □  None 
     □ Effective/clinically proven                                           □ Not habit forming  
     □ Works to correct chemical imbalance                          □ Won’t change your personality    
     □ Product has been studied for X length of time             □ Convenient                     
     □ Treats Pre Menstrual Dysphonic Disorder                   □ Most prescribed/used                   
     □ Product helps treat Post Traumatic Stress Syndrome   □ Rapid Relief                     
     □ Low occurrence of side effects/not usually serious/well tolerated                        
     □ Not associated with weight gain                                                                        
□ Other_________________________________ 
 
 General information about depression              □  None 
 (check all that apply) 
General: 
 □ Depression is a serious medical condition/can interfere with daily functioning 
□ Depression affects millions/one of most common illnesses  
 □ Different treatments may have different results in different people 
 □ It can be triggered by stressful life, or it can appear suddenly                     
 □ When you’re clinically depressed the level of serotonin may drop 
 □ Depression is a real illness with real causes 
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 □ The cause of depression is unknown 
□ Depression could be caused by a chemical imbalance 
□ Depression includes both emotional and physical symptoms 
□ PMDD is related to hormonal changes and chemicals in your body 
 
Symptoms 
□ Everyday life unbearable     □ Inability to Concentrate     □ Loss of Interest    
□ Change in Sleep Patterns     □ Change in appetite     □ Fatigue/Low energy    
□ Thoughts of Death/Suicide  □ Depression/Sadness     □ Sadness lasts weeks     
 □ High Stress/Anxiety           □ Agitation/irritability     □ Restlessness 
 
□ Other__________________________________________________ 
     
    Additional Information (check all that apply)               □  None 
 □ No additional information      □ Address     □ Phone Number                  
 □ Contact system                       □ Website                                                                                  
                             □ Other________________________________ 
    Offerings (check all that apply)                 □  None 
  □ Support system/program                      □ Coupons and discounts         □ Self-Test      
   □ Free/more information or booklet       □ Questionnaire                      
                           
Nature of Ad Appeal (check all that apply) 
□ Anecdotal/Testimonial                      □ Humor/Witty           □ Popular Appeal 
 □ Motivational                                      □ Fear-based              □ Safety 
 □ Informative/Statistics & Studies       □ Promotional                
                                                           
  Superiority Claims               □  None 
            □ Comparison Product(s)               □ General Comparison 
   Which Product:______________________ 
   Basis of Comparison:__________________ □ FTC Report    □ FTC Method    □ Either 
   Text of claim_______________________________________ 
People in ad?                           □ People                  □ No people 
                     □  Anthropomorphic Character   
 
   People in foreground of ad 
   Person 1          Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other      □ CBI 
                          Gender   □ Male       □ Female                                                              □ CBI 
                          Age        □ Child       □ Teen      □ Adult          □ Elder                         □ CBI    
                          Using Product           □ Yes        □ No       
                          Celebrity                   □ Yes_____________________       □ No 
                          Occupation _________________________________       □ Not specified 
              Health of Person 1 (check all that apply) 
 
   Person 2          Race      □ White      □ Black     □ Hispanic     □ Asian     □ Other      □ CBI  
                          Gender   □ Male       □ Female                                                              □ CBI 
 144 
 
                          Age        □ Child       □ Teen      □ Adult          □ Elder                         □ CBI   
                          Using Product           □ Yes        □ No       
                          Celebrity                   □ Yes_____________________       □ No 
                          Occupation _________________________________       □ Not specified 
 
   Person 3         Race       □ White      □ Black     □ Hispanic     □ Asian     □ Other      □ CBI 
                          Gender   □ Male       □ Female                                                              □ CBI 
                          Age        □ Child       □ Teen      □ Adult          □ Elder                         □ CBI    
                          Using Product           □ Yes        □ No       
                          Celebrity                   □ Yes_____________________       □ No 
                          Occupation _________________________________       □ Not specified 
               
   Person 4         Race       □ White      □ Black     □ Hispanic     □ Asian     □ Other       □ CBI 
                          Gender   □ Male       □ Female                                                               □ CBI 
                          Age        □ Child       □ Teen      □ Adult          □ Elder                          □ CBI    
                          Using Product           □ Yes        □ No       
                          Celebrity                   □ Yes_____________________       □ No 
                          Occupation _________________________________       □ Not specified 
               
   Person 5         Race       □ White      □ Black     □ Hispanic     □ Asian     □ Other       □ CBI 
                          Gender   □ Male       □ Female                                                               □ CBI 
                          Age        □ Child       □ Teen      □ Adult          □ Elder                          □ CBI    
                          Using Product           □ Yes        □ No       
                          Celebrity                   □ Yes_____________________       □ No 
                          Occupation _________________________________       □ not specified         
 
 
  Group of People                        □ Yes                      □ No 
                                                      Number of people in group: _______               □ CBI 
 
 Group characteristics    (Check all that apply) 
                  Race       □ White      □ Black     □ Hispanic     □ Asian     □ Other       □ CBI 
                  Gender   □ Male       □ Female                                                               □ CBI 
                  Age        □ Child       □ Teen      □ Adult          □ Elder                          □ CBI         
                  Celebrity                   □ Yes_____________________       □ No 
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